Podcasts about emr

AI is being added to everything — from your EMR to your phone system — but adding technology alone doesn't guarantee better results. For private practices, the real question isn't “Should we use AI?” but rather “Will it actually solve the root problems holding us back?” In this episode, Zed breaks down how to evaluate AI tools the right way. You'll learn how to separate hype from true value, identify whether your challenges are system or human-based, and set clear metrics to measure success before you commit. If you've ever wondered whether AI can actually improve your practice — or just add another layer of complexity — this episode will give you the framework to decide. Request a Practice Review: https://www.physiciangrowthaccelerator.com/connect  Take the Vitals Diagnostic: https://www.physiciangrowthaccelerator.com/vitals-diagnostic 

Dr. Monique Diaz, Chief Medical Informatics Officer at CommonSpirit Health, unpacks the intersection of big data, clinical care, and healthcare innovation. She shares how informatics transforms resource allocation, patient engagement, and system efficiency—while offering a behind-the-scenes look at the daily responsibilities of a CMIO, from EMR coding to AI integration. Dr. Diaz also explores the evolving relationship between informatics and AI, and how future advancements hinge on ethical frameworks and responsible governance. Check out Chadi's website for all Healthcare Unfiltered episodes and other content. www.chadinabhan.com/ Watch all Healthcare Unfiltered episodes on YouTube. www.youtube.com/channel/UCjiJPTpIJdIiukcq0UaMFsA

SLP malpractice insurance without ASHA Membership (or the CCC), fact or fiction? In this Fix SLP Summer School episode, Dr. Jeanette Benigas, SLP, and Preston Lewis, MS/SLP, discuss affordable liability coverage options for licensed SLPs who choose not to maintain ASHA membership or the CCC. They explain the ProLiability/AMBA partnership, why it's not your only option, what policies and riders are important (malpractice, general liability, E&O, license defense), and how to shop smart for rates that fit your risk and setting.Plus: our first sponsor, ⭐️ Remedy ⭐️, an EMR built by SLPs, offering early access with 50% off your first two months. Check them out! PLUS, a quick Michigan update: Health Policy Committee vote scheduled for HB 4484.New here? Subscribe, share with a colleague, and call the Minivan Meltdown line at fixslp.com to add your voice.

In this HealthImpact Live Podcast episode, Michael Rogozinski, healthcare leader and executive at Vital.io, joins Janae Sharp for a timely conversation about transforming patient experience in real-time. They'll discuss how Vital's platform leverages live EHR data and healthcare AI to guide millions of patients through hospital, emergency, and urgent care visits—simplifying complex medical interactions and making care more transparent.This conversation will explore:Why the patient experience is central to better outcomes and satisfactionHow real-time data and AI can improve communication and reduce clinician workloadThe role of technology in predicting wait times, guiding care, and supporting discharge planningJoin us to learn how creating a better healthcare experience isn't just about convenience—it's about delivering safer, smarter, and more human-centered care.Michael A. Rogozinski, Chief Nursing Officer, Vital.ioMegan Antonelli, Founder & CEO, HealthIMPACT Live

Hat das OLG Köln mit seinem Urteil vom 23.05.2025, 15 UKl 2/25, das KI Training durch Meta –abschließend – gestattet, welche Auswirkungen hat diese Entscheidung auf die datenschutzrechtliche Bewertung des Trainings von KI oder sogar auf deren Nutzung – und wäre die Entscheidung anders ausgefallen, wenn ein Verwaltungsgericht entschieden hätte? Im Interview klärt Kristin Benedikt (Richterin am Verwaltungsgericht Regensburg, von 2015-2020 Leitung des Bereichs Internet beim Bayerischen Landesamt für Datenschutzaufsicht, Mitglied des Vorstands der GDD Gesellschaft für Datenschutz und Datensicherheit e. V. und des Instituts für Europäisches Medienrecht e.V. (EMR)) diese Fragen auf und gibt einen weitreichenderen Blick auf die Auswirkungen der Entscheidung!Das weitgreifende Komplettangebot inklusive Formulare zu DSGVO/TTDSG/BDSG im Beratermodul Datenschutzrecht. 4 Wochen gratis nutzen! ⁠ottosc.hm/dsgvo⁠

Where are you wasting money in your business — and where are you not investing enough?In this episode, we break down the biggest money mistakes we see pelvic business owners make. Spoiler: it's not about whether something feels “expensive,” it's about Return on Investment (ROI).

Growth and profitability all starts with having solid financial data. Without it, you're basically flying blind.Financial expert Jessica Nunn shares the top five best and worst things aesthetic practices can do when it comes to their bottom line. When you understand your finances, you can actually be profitable instead of just hoping for the best.Jessica breaks down some of the most common mistakes she sees from her work with hundreds of aesthetic professionals of all sizes and stages of growth. About Jessica NunnJessica Nunn founded Maven Financial with a vision to make strategic financial advice accessible to every small business owner. She understands that her clients carry the responsibility of maintaining a business, meeting their goals, paying their employees, paying themselves, and providing for their families. Her job is to make the complex world of revenue, profitability, and key performance indicators clear and simple. Learn more about Maven Financial PartnersFollow Maven Financial Partners on Instagram @mavenfinancialGuestJessica Nunn, Founder & CEOMaven Financial PartnersHostRobin Ntoh, VP of AestheticsNextechPresented by Nextech, Aesthetically Speaking delves into the world of aesthetic practices, where art meets science, and innovation transforms beauty.With our team of experts we bring you unparalleled insights gained from years of collaborating with thousands of practices ranging from plastic surgery and dermatology to medical spas. Whether you're a seasoned professional or a budding entrepreneur, this podcast is tailored for you.Each episode is a deep dive into the trends, challenges, and triumphs that shape the aesthetic landscape. We'll explore the latest advancements in technology, share success stories, and provide invaluable perspectives that empower you to make informed decisions.Expect candid conversations with industry leaders, trailblazers and visionaries who are redefining the standards of excellence. From innovative treatments to business strategies, we cover it all.Our mission is to be your go-to resource for staying ahead in this ever-evolving field. So if you're passionate about aesthetics, eager to stay ahead of the curve and determined to elevate your practice, subscribe to the Aesthetically Speaking podcast.Let's embark on this transformative journey together where beauty meets business.About NextechIndustry-leading software for dermatology, medical spas, ophthalmology, orthopedics, and plastic surgery at https://www.nextech.com/ Follow Nextech on Instagram @nextechglowAesthetically Speaking is a production of The Axis: theaxis.io Theme music: I've Had Enough, Snake City

This episode is sponsored by: My Financial CoachYou trained to save lives—who's helping you save your financial future? My Financial Coach connects physicians with CFP® Professionals who specialize in your complex needs. Whether it's crushing student loans, optimizing investments, or planning for retirement, you'll get a personalized strategy built around your goals. Save for a vacation home, fund your child's education, or prepare for life's surprises—with unbiased, advice-only planning through a flat monthly fee. No commissions. No conflicts. Just clarity.Visit myfinancialcoach.com/physiciansguidetodoctoring to meet your financial coach and find out if concierge planning is right for you.———————In this episode, Dr. Bradley Block  welcomes Dr. Michael  Hersh, to explore the common challenge of career stagnation in medicine. After years of routine patient care, Dr.  Hersh found himself questioning, “Is this it?” Through coaching, he rediscovered joy by embracing new ventures like podcasting and coaching other physicians. He discusses strategies to combat burnout, including learning new skills, setting firm boundaries, and practicing self-compassion to balance work and family life. As host of Better Physician Life: How to Get Unstuck in Your Medical Career, Dr.  Hersh offers practical tools to help physicians redefine success, stay present, and find fulfillment. This episode is a must-listen for doctors feeling stuck and seeking renewed purpose.Three Actionable Takeaways:Embrace New Challenges – Combat stagnation by learning something new, like a hobby, side project, or podcasting, to reignite the joy of growth and keep your career dynamic.Set Firm Boundaries – Establish clear work-life boundaries, like reserving family time or managing EMR tasks strategically, to reduce stress and enhance presence at home.Practice Self-Compassion – Forgive yourself for missing occasional events (e.g., a child's concert) by focusing on your consistent presence, ensuring balance without guilt.About the ShowSucceed In Medicine  covers patient interactions, burnout, career growth, personal finance, and more. If you're tired of dull medical lectures, tune in for real-world lessons we should have learned in med school!About the GuestDr. Michael Hersh is a full-time gastroenterologist, physician coach, and host of Better Physician Life: How to Get Unstuck in Your Medical Career on the Doctor Podcast Network. With over 16 years in practice, he helps physicians overcome burnout, set meaningful goals, and achieve work-life balance through his coaching practice, Better Physician Life Coaching. Dr. Hersh's journey from career stagnation to renewed purpose inspires doctors to rethink success and embrace new opportunities.Website: betterphysicianlife.comPodcast: Better Physician Life: How to Get Unstuck in Your Medical CareerLinkedIn: https://www.linkedin.com/in/michael-hersh-mdInstagram: https://www.instagram.com/betterphysicianlifeAbout the hostDr. Bradley Block – Dr. Bradley Block is a board-certified otolaryngologist at ENT and Allergy Associates in Garden City, NY. He specializes in adult and pediatric ENT, with interests in sinusitis and obstructive sleep apnea. Dr. Block also hosts The Succeed In Medicine  podcast, focusing on personal and professional development for physiciansWant to be a guest?Email Brad at brad@physiciansguidetodoctoring.com  or visit www.physiciansguidetodoctoring.com to learn more!Socials:@physiciansguidetodoctoring on Facebook@physicianguidetodoctoring on YouTube@physiciansguide on Instagram and Twitter   This medical podcast is your physician mentor to fill the gaps in your medical education. We cover physician soft skills, charting, interpersonal skills, doctor finance, doctor mental health, medical decisions, physician parenting, physician executive skills, navigating your doctor career, and medical professional development. This is critical CME for physicians, but without the credits (yet). A proud founding member of the Doctor Podcast Network!Visit www.physiciansguidetodoctoring.com to connect, dive deeper, and keep the conversation going. Let's grow! Disclaimer:This podcast is for informational purposes only and is not a substitute for professional medical, financial, or legal advice. Always consult a qualified professional for personalized guidance.

Send us a textMost of us go to the doctor, get labs drawn, maybe even have a scan — and then never see the full picture of our own health. That's changing.In this episode of The Daily Apple, Kevin talks with Travis Bond, founder of Bio Insights, about the future of electronic medical records (EMRs) and why they're not just for doctors. EMRs are becoming the backbone of how patients can actually see, understand, and act on their health information.This isn't a tech episode for physicians. It's a conversation about how you can be more connected, informed, and in charge of your own health journey. From making sure your care team is on the same page, to finally having your results and history in one place, EMRs are making it possible to move from confusion to clarity.In this episode:Why electronic medical records matter for patients, not just providersHow EMRs make it easier to track your own progress over timeThe difference between “data overload” and “actionable information”How a more connected record leads to better conversations with your doctorWhat the future looks like when patients actually own their health storyIt's not about replacing your doctor. It's about having the tools to understand what's happening — and make decisions with confidence. Prime Health Associates

Dr. Wilner would love your feedback! Click here to send a text! Thanks!Many thanks to Rashie Jain for joining me on this episode of The Art of Medicine with Dr. Andrew Wilner!  Rashie is an engineer and Co-Founder of Marvix.AI, her second start-up. Rashie observed that many physicians struggle with high administrative burdens, especially medical specialists who spend more time with patients and deal with complex cases. With the advent of large language models, she created an "ambient scribe" that takes notes during a patient encounter, organizes them, and presents them for review as a finished product. With just a little tweaking, doctors can embed these notes into the electronic medical record (EMR). I tried out Rashie's software at the recent American Academy of Neurology meeting in San Diego, CA. Her Co-Founder played the role of a migraine patient, and we chatted for about 10 minutes. Truth be told, the ambient scribe did a great job capturing the essential details. I could have edited it in just a couple of minutes, which would save time compared to typing it into the EMR myself! To learn more about Marvix.AI, or to try it in your own office, please contact Rashie Jain at https://www.marvixapp.ai#AI #ambientscribe #largelanguagemodel #womenentrepreneurPlease click "Fanmail" and share your feedback!If you enjoy an episode, please share with friends and colleagues. "The Art of Medicine with Dr. Andrew Wilner" is now available on Alexa! Just say, "Play podcast The Art of Medicine with Dr. Andrew Wilner!" To never miss a program, subscribe at www.andrewwilner.com. You'll learn about new episodes and other interesting programs I host on Medscape.com, ReachMD.com, and RadioMD.com. Please rate and review each episode. To contact Dr. Wilner or to join the mailing list: www.andrewwilner.com Finally, this production has been made possible in part by support from “The Art of Medicine's” wonderful sponsor, Locumstory.com, a resource where providers can get real, unbiased answers about locum tenens. If you are interested in locum tenens, or considering a new full-time position, please go to Locumstory.com. Or paste this link into your browser: https://locumstory.com/?source=DSP_directbuy_drwilnerpodcast_ph...

In a business climate shaped by rapid technological disruption, shifting geopolitical landscapes, and evolving customer expectations, strategy cannot remain static. JD Carter, Chief Strategy Officer at Vasion, believes the key to success lies in constantly aligning vision with execution while adapting to market realities in real time. In this conversation, JD shares how his role involves continuously monitoring external signals such as technology shifts, regulatory changes, and economic pressures, then translating those insights into operational action. We explore his approach to looking beyond the company vision by breaking it down into achievable missions that link long-term goals with day-to-day work across cross-functional teams. A major focus of the discussion is AI readiness and how organisations can move beyond hype to real impact. JD outlines a five-stage process for becoming AI-ready, starting with digitising and centralising documents and data, followed by cleaning and structuring information for use with large language models. He explains how automating repetitive workflows, modernising infrastructure, and ensuring interoperability across systems such as ERP and HR platforms create the foundation for orchestrated automation at scale. Governance and access controls complete the picture, ensuring that AI deployment meets both internal and regulatory standards. We also look at how Vasion balances short-term market needs with a long-term platform vision. JD describes how leveraging the company's market-leading print infrastructure products supports current growth, while investing in R&D drives the development of a multi-product SaaS platform designed to integrate AI across the enterprise. A customer-first mindset shapes every decision, from pricing to product development, with continuous engagement through advisory boards, surveys, and direct conversations ensuring that partner strategies align with customer priorities. To illustrate these principles in action, JD shares how Vasion responded to market demand for system-generated print job support by developing a SaaS-based output automation product. This pivot addressed a gap created by ERP and EMR vendors moving customers to the cloud and positioned Vasion at the start of its multi-product journey. We discuss the signals leaders should watch to keep strategy relevant, including shifts in customer behaviour, the pace of technology adoption, and internal friction that may indicate misalignment. JD likens strategy to a GPS system, with vision as the destination and constant recalibration required to navigate roadblocks and changing conditions. The conversation closes with a focus on embedding strategic agility into company culture. JD explains Vasion's Missions of Aspirational Performance system, which connects corporate values directly to execution by breaking down strategic goals into work that individuals can see contributing to the bigger picture. He also shares his personal three-pronged approach to continuous learning, combining formal education, informal learning, and mentor-driven guidance. This episode offers practical insight for leaders navigating uncertainty, balancing present-day demands with future opportunity, and embedding adaptability into the DNA of their organisations.

Hat das OLG Köln mit seinem Urteil vom 23.05.2025, 15 UKl 2/25, das KI Training durch Meta –abschließend – gestattet, welche Auswirkungen hat diese Entscheidung auf die datenschutzrechtliche Bewertung des Trainings von KI oder sogar auf deren Nutzung – und wäre die Entscheidung anders ausgefallen, wenn ein Verwaltungsgericht entschieden hätte? Im Interview klärt Kristin Benedikt (Richterin am Verwaltungsgericht Regensburg, von 2015-2020 Leitung des Bereichs Internet beim Bayerischen Landesamt für Datenschutzaufsicht, Mitglied des Vorstands der GDD Gesellschaft für Datenschutz und Datensicherheit e. V. und des Instituts für Europäisches Medienrecht e.V. (EMR)) diese Fragen auf und gibt einen weitreichenderen Blick auf die Auswirkungen der Entscheidung!Das weitgreifende Komplettangebot inklusive Formulare zu DSGVO/TTDSG/BDSG im Beratermodul Datenschutzrecht. 4 Wochen gratis nutzen! ⁠ottosc.hm/dsgvo⁠

In this bonus episode of Leaders in Medical Billing, we're bringing you the full replay of our most recent, live webinar: AI for Patient Billing. Hosted by Chanie Gluck, this session features a deep dive into how artificial intelligence is transforming one of the most overlooked — and increasingly critical — parts of the revenue cycle. You'll hear from two seasoned RCM leaders actually using AI in the field: Jeff Robertson, CEO of Nexus, shares how AI tools like Raxia helped one client double monthly patient payments and reduce average days to payment by over 50%. John Gwin, CEO of Auctus Group, walks us through his experience using Inbox Health and other platforms to boost collection velocity while maintaining a strong patient experience. They break down: The shift in revenue mix and why patient payments can no longer be ignored How to evaluate and select AI tools based on EMR integration, pricing models, and long-term ROI The importance of front desk processes — from capturing contact details to coaching staff on payment conversations Real-world metrics, implementation timelines, and what to expect as these platforms evolve Whether you're new to AI or already exploring automation, this episode is packed with tactical insights and hard-won lessons to help you stay ahead.

In this episode of Healthcare Americana, host Christopher Habig talks with Dr. Shannon Decker, CEO of VBC One, about what value-based care (VBC) really means and how it differs from traditional fee-for-service models. Dr. Decker explains that VBC focuses on prevention, quality measures, total cost of care, and accurate risk adjustment. She discusses payment approaches like capitation with quality bonuses and highlights the practical needs for success, including strong EMR documentation, risk coding, clinician and patient engagement, interoperable data, and effective workflows. The conversation also covers pitfalls such as underreported chronic conditions, challenges with global risk contracts like ACO REACH, and the importance of contract protections and ongoing education. Dr. Decker emphasizes that with the right systems and trust between clinicians and patients, value-based care can improve outcomes and reduce costs, but it requires careful planning and implementation.More on Freedom Healthworks & FreedomDoc HealthSubscribe at https://healthcareamericana.com/More on Dr. Shannon Decker & VBC OneFollow Healthcare Americana: Instagram & LinkedIN

In the second episode of our conversations with APAC health IT leaders on their EMR experience, we dive into the complexities of the technology's implementation down under. Our guests share insights on navigating challenges like interoperability, third-party integrations and data exchange journeys. They also discuss the impact of statewide consultations and regional alliance groups on feature implementation and provide their perspectives on the evolution of My Health Record.

Send us a textEver had an amazing IVF cycle followed by one that made you question everything? You're not alone—and no, your ovaries didn't suddenly revolt. In this episode of Taco Bout Fertility Tuesday, Dr. Mark Amols breaks down the statistical concept of regression to the mean—why extreme fertility outcomes often return to average over time.From IVF cycles to PGT results, hormone levels to semen analysis, you'll learn why bouncing numbers aren't always bad—and why your “worst cycle ever” might just be math doing its thing. Packed with analogies, real patient stories, and just enough nerdy data to make you feel smarter than your doctor's EMR, this episode is for anyone riding the emotional rollercoaster of fertility treatment.

In this episode of The Dish on Health IT, Tony Schueth and Rob Dribbon are joined by Neikisha Charles Director of Quality Improvement and Risk Management of Bedford Stuyvesant Family Health Center (Bed-Stuy), a federally qualified health center (FQHC) in Brooklyn, NY. Together, they dig into common misconceptions about FQHCs and shine a spotlight on the opportunities they present for strategic engagement across the healthcare ecosystem—especially for health IT and life sciences organizations.Neikisha opens with her personal journey: starting as a data analyst at Bed-Stuy in 2021 and quickly rising into her current leadership role because of her knack for using data to drive quality improvement. Her story illustrates the increasing sophistication of FQHCs and sets the tone for a broader conversation about how these organizations are evolving.To help orient listeners who may not fully understand the role of FQHCs, Neikisha provides a clear definition: FQHCs are federally funded community-based providers mandated to offer care to all residents in underserved areas, regardless of insurance status. They are deeply attuned to social determinants of health and committed to removing access barriers for vulnerable populations.Rob adds context from his years in pharma, highlighting the unique value proposition of FQHCs—namely, their holistic and integrated approach to care. He urges listeners not to overlook these organizations simply because they've historically focused on commercial health systems.Neikisha then debunks a major myth: that FQHCs only serve uninsured or homeless patients. In fact, Bed-Stuy primarily serves Medicaid-managed populations, but also sees commercially insured and uninsured individuals, offering services on a sliding scale. Services range from primary care and mental health to dental, podiatry, and optometry, along with extensive care coordination and social support services.When asked what health IT vendors and life sciences companies may be missing, Neikisha makes it clear: FQHCs are not tech or data-poor. Bed-Stuy uses a robust EHR (eClinicalWorks), the Azara DRVS population health platform, and Artera for two-way patient communication. These tools aren't just window dressing—they are integrated into care delivery to close gaps, improve compliance, and monitor population health in real time.She offers a compelling case study: When colorectal cancer screening rates began to drop, Neikisha led a data-driven campaign using Azara to identify noncompliant patients, Artera to send targeted outreach texts, and a partnership with Exact Sciences to offer Cologuard kits to patients by mail. The result? A 12.3% increase in screening compliance over 18 months.Rob underscores the significance of this approach—not just the smart use of technology, but also the community-level relationships and the trust that make this kind of intervention effective.The discussion then shifts to interoperability. Neikisha notes the complexities of data exchange and the importance of dedicated roles like a Director of Health Integration to manage relationships and reporting. Bed-Stuy is connected to a regional health information organization (RHIO), uses platforms like Azara to track transitions of care, and maintains read-only EMR access with key partners to streamline care coordination. While true vendor-agnostic interoperability remains elusive, FQHCs are actively working with what's available.Tony brings the conversation back to the bigger picture: What gaps do vendors and life sciences partners need to close? Neikisha points to the need for better education about what FQHCs actually do and who they serve. She challenges companies to co-create solutions with FQHCs—offering tools that reflect real-world workflows and support sustainable partnerships rather than transactional engagements.The episode wraps with both Rob and Neikisha emphasizing the untapped potential of FQHCs. With over 30 million Americans relying on them for care, these organizations are not fringe players—they are essential infrastructure. And as Neikisha puts it, they're “here to stay.” To partner successfully, the first step is simple: reach out, learn what's needed, and build something meaningful together.Related ContentWhat Are FQHCs, & Should Life Sciences Manufacturers Even Care About Them?HIT Perspectives May 2025: FQHC Myth vs Fact Bedford Stuyvesant Family Health Center Brooklyn NY - Primary Care Services 

Summary In this conversation, the panel discusses various challenges in the healthcare industry, focusing on the roles of students in medical practices, the complexities of Medicaid, and the implications of proposed CMS regulations on skin substitutes. They emphasize the importance of compliance, accurate documentation, and the need for providers to be aware of the evolving landscape of healthcare regulations and billing practices.TakeawaysStudents cannot perform or do any work that is billable and reimbursable.Documentation is key to halting audits and investigations.Medicaid faces challenges with enrollment and funding.Providers must understand the billing rules for students and graduates.AI can lead to cloning in documentation if not used carefully.Vendors must be held accountable for their products and claims.The EMR is a tool that requires proper management and understanding.Medicaid managed care plans can be poorly managed and lead to issues.Providers need to be cautious of schemes in billing practices.Skin substitutes are becoming a focal point for compliance and billing scrutiny.

Clinical Practice Guidelines (CPGs) are an incredible resource for clinicians of all experience levels—synthesizing all the research on a topic and packaging it into bite-sized recommendations and flow charts. But how often are clinicians adhering to these guidelines? In today's episode, Dr Maggie Horn (Duke University) walks us through her research team's work to assess if, how, and when clinicians follow CPG recommendations. The team worked with clinicians in their hospital system to embed templates in the EMR, and used self-report strategies to answer these questions, specifically for the neck pain CPG. Dr Horn reviews the neck pain CPG, how the research team evaluated adherence, and what the findings mean for CPGs and clinicians. ------------------------------ RESOURCES Neck pain clinical practice guideline (revised in 2017): https://www.jospt.org/doi/10.2519/jospt.2017.0302 Translating the neck pain CPG into practice framework: https://www.jospt.org/doi/10.2519/josptopen.2025.0101

What if a Marketing Company Designed an EMR?

Dr. Vitor Asseituno is the CEO and Co-Founder of Sami, Brazil's fastest-growing health insurance startup. Sami has raised $65M total funding and serves 20,000+ customers across 11 Brazilian cities in the $60B private health insurance market.Key Insights & Takeaways:1. The "pipeline mathematics" behind turning 100+ VC rejections into Series B success2. Investor psychology: what resonates when pitching complex healthcare business models3. How embracing broker networks after everyone said "avoid them" drives 50%+ of sales4. AI workflow implementation: $800+ monthly savings per clinician and 30% EMR compliance improvement5. Loss ratio optimization tactics: the specific changes that improved margins from 85% to 53%6. Why regional focus beats national scale in Brazil's complex healthcare marketJoin The J Curve Community:Newsletter: Weekly deep dives into LATAM's hottest deals, emerging trends, and market intelligenceLinkedIn: Daily market insights and exclusive founder updatesInstagram: Behind-the-scenes podcast moments and quick industry takesHit subscribe and share this episode with fellow entrepreneurs and investors

Bald endet sie, diese EM 2025, die zum Schweizer Fussballfest wurde. Volle Stadien überall, ein gigantischer Fanmarsch und die Dramaturgie passte auch noch. Man denke nur an das späte Tor von Riola Xhemaili in der Gruppenphase, das das Stade de Genève in Ekstase stürzte. Oder an die vielen Spiele, die in der Verlängerung oder im Penaltyschiessen entschieden wurden. So dass Freud und Leid immer besonders nah beieinander waren. Am Sonntag tragen die Spanierinnen und die Engländerinnen die letzte Partie dieser EM aus. Es geht nur noch um eines: diesen Pokal zu gewinnen. Bevor aber alles endet und sich der Schweizer Fussball wieder dem Alltag widmet, blicken wir in der 299. Folge unseres Fussball-Podcasts zurück auf die letzten vier Wochen.Wir tun das mit Noa Schärz, seit kurzem ehemalige Fussballerin. Mit YB wurde sie vor einigen Wochen Schweizer Meisterin, dann entschied sie sich für eine Auflösung ihres Vertrags. Sie sagt, warum sie das tat. Und erklärt, warum diese EM nicht nur eine sportliche, sondern auch eine politische und gesellschaftliche Komponente hat. Hosts: Marcel Rohner und Loris BrasserProduzent: Noah FendDie Themen:00:00 Intro02:44 Noa Schärz' Karriereende12:15 EM-Rückblick47:50 Vorschau EM-Final In der Dritten Halbzeit wird über den Schweizer Fussball diskutiert.

You have heard about AI everywhere, and now it is being used within EMR services. If you feel unsure about this topic or you want to learn more, then definitely play this episode and join us for the conversation! In this podcast episode, Catharine from Jane App and I discuss how Jane App incorporates AI into their EMR, including some general best practice guidelines about how you can use to use Jane's AI Script services ethically and safely in your practice.  MEET CATHARINE Catharine Martin is the Privacy and Compliance Manager at Jane App, where she plays a key leadership role in shaping and overseeing the company's privacy and regulatory strategies. With a strong background in data protection and compliance, she works closely with healthcare practitioners to ensure their practices meet evolving privacy requirements while also finding practical ways to reduce administrative burden. Beyond her work at Jane, Catharine is also a dedicated Pilates instructor, bringing the same focus and discipline to her teaching as she does to her professional work. Learn more about Catharine on her LinkedIn profile.  In this episode:  Working with Jane App  AI Scribe AI in client diagnostics  It is all up to you  Jane's appearance in The Globe and Mail  Working with Jane App Catharine, 20 years ago, after giving birth, had a radical and unexpected medical event that left her in a brief coma, experiencing multiple organ failure.  However, due to her incredible doctors, her strength, and a lot of luck, she survived and kept all her organs, without needing any transplants, and went on to make a full recovery.  How did this bring her to work for Jane App? After what Catharine went through, she felt so drawn to Jane App's vision to “Help the helpers”, that she started working for the company to further their mission.  AI Scribe Jane App offers an AI scribe feature. It essentially charts notes from your sessions with clients in your own voice.  Jane secured a third-party vendor who is known for their robust privacy practices, which are all compliant with the required ethical laws and privacy legislation, to help them integrate the AI tool.  AI in client diagnostics ‘As part of using Jane's AI Scribe, therapy notes are included, but not diagnostic suggestions. As in, diagnostic suggestions are not coming from any AI-powered tool. Diagnostic suggestions are coming from a human, providing care to another human.' - Catharine Martin  Even though Jane App makes use of AI in some of their service offerings, they are critical of making sure that it is being used ethically and appropriately, and only for admin-related tasks.  The care suggestions and client diagnostics will still only come from you, the client's therapist, based on your sessions together. It is all up to you With your Jane App subscription, when it comes to AI, it is all up to you. You don't have to make sure of it, even though it is being offered to you.  You can easily opt in or out of using it within your Jane App subscription, hassle-free.  Also, consider the risk of any tool that you use when you are weighing up whether to use it or not.  Jane's appearance in The Globe and Mail Jane App made great headlines in one of The Globe and Mail's articles for reaching a $1.8-billion valuation.  Jane App is looking to adopt AI on a grand scale by continuing to explore its benefits ethically to help more helpers.  Connect with me: Instagram Website  Resources mentioned and useful links: Ep 169: Rachel Brennan: Keeping Connection in an Online Group Practice | EP 169  Learn more about the tools and deals that I love and use for my Canadian private practice Sign up for my free e-course on How to Start an Online Canadian Private Practice Jane App (use code FEARLESS for one month free) Get some help and freebies on your website with WordPress!  Learn more about Catharine on her LinkedIn profile Rate, review, and subscribe to this podcast on Apple Podcasts, Spotify, Amazon, and TuneIn

Welcome to the Sustainable Clinical Medicine Podcast! In this special cross-pollinated episode, Dr. Sarah Smith sits down with Dr. Siobhan Key and Dr. Jessie Mahoney—two fellow physician coaches and long-time collaborators—for a candid conversation about reframing life and work in medicine for greater sustainability. As the panel reflects on the past year and looks forward to 2025, they open up about personal growth, big life transitions, and how each of them is intentionally crafting a more fulfilling and balanced life both inside and outside the clinic. Listen in as Dr. Smith shares her journey of returning to Australia and embracing new adventures, Dr. Mahoney discusses building a retreat center and leaning into new opportunities, and Dr. Key explores the importance of replenishment, self-reflection, and pursuing passions beyond medicine. Together, they offer practical insights on adapting to change—whether it's integrating new technologies like AI scribing or simply surviving a new EMR rollout—and they speak honestly about the discomfort, excitement, and learning that comes with growth. This episode is filled with tips for creating sustainable routines, reflections on personal and professional development, and encouragement to embrace both the challenges and rewards of transformation. Whether you're a seasoned physician or just starting your practice, you'll find reassurance and inspiration in the stories, strategies, and camaraderie shared in today's discussion. Let's dive in! Here are 3 key takeaways from this episode: Embrace Change at Your Own Pace: Whether it's new technology like AI scribing or a shift in your clinical environment, remember that adapting is a process—not a race. Give yourself grace and patience as you work through the inefficiencies and discomfort that accompany change (you're not alone in feeling overwhelmed at times!). Intentional Reflection Fuels Growth: Instead of traditional resolutions, try reflecting on the past year—what you're proud of, what challenged you, and what you truly want in the year ahead. For us, themes like connection, adventure, belonging, and “more me” set the tone for 2024. Connection & Coaching Matter: Sharing your struggles and wins—whether in group coaching, with a colleague, or through community—reduces isolation and leads to creative solutions. Investing in yourself (through coaching or peer support) isn't just valuable, it's transformative for your career and well-being. Letting Go of Frustration and Embracing Change Dr. Jessie Mahoney, a mindfulness coach and yoga instructor, shared a powerful analogy from her life. She recently moved to the countryside, where a creek outside her home serves as a daily reminder of how life ebbs and flows. Some days, the creek is calm and quiet; other days, it's noisy and chaotic. She's learned to embrace these shifts, recognizing that frustration only makes the hard moments harder. For physicians, this perspective is invaluable. Whether it's navigating a new workflow or dealing with workplace changes, letting go of frustration and focusing on what you can control can make all the difference. Asking for What You Need Dr. Sarah Smith has been adjusting to life and work in a new country, and she shared a simple but effective strategy: step back and ask yourself, What do I need to make this work for me? Whether you're facing a new team dynamic or adapting to technological shifts in your practice, pausing to evaluate your needs—and advocating for them—can help you approach change with confidence instead of overwhelm. -------------- Would you like to view a transcript of this episode? Click here **** Charting Champions is a premiere, lifetime access Physician only program that is helping Physicians get home with today's work done. All the proven tools, support and community you need to create time for your life outside of medicine. Learn more at https://www.chartingcoach.ca **** If you would like more information on the other two doctors on this podcast episode. Jessie Mahoney can be found at www.jessiemahoneymd.com Siobhan Key can be found at https://weightsolutionsforphysicians.ca/ **** Enjoying this podcast? Please share it with someone who would benefit. Also, don't forget to hit “follow” so you get all the new episodes as soon as they are released. **** Come hang out with me on Facebook or Instagram. Follow me @chartingcoach to get more practical tools to help you create sustainable clinical medicine in your life. **** Questions? Comments? Want to share how this podcast has helped you? Shoot me an email at admin@reachcareercoaching.ca. I would love to hear from you.

Episode 197: Continuous Glucose MonitoringWritten by William Zeng, MSIII, and Chris Kim, MSIII. University of Southern California.You are listening to Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Will: IntroToday we're exploring Continuous Glucose Monitoring, or CGM. We'll break down what CGM is, who benefits, how to access it, options available for our patients, the pros and cons, and a few final reflections on where this technology is heading. Chris, So what is CGM?Chris:Continuous glucose monitoring refers to the use of a small wearable sensor placed just under the skin to track glucose levels in real time throughout the day and night. These sensors measure glucose in the interstitial fluid and transmit readings to a receiver or smartphone at regular intervals, allowing for 24/7 glucose trend tracking. Will:CGM has been shown to improve glycemic control, increase “time in range,” and reduce hypoglycemia. Let's review some evidence.Chris:A 2023 meta-analysis published in Diabetes Technology & Therapeutics reported a mean Hemoglobin A1c reduction of 0.43% across multiple trials. Will:In people with Type 1 diabetes, the IMPACT and DIAMOND studies showed sustained improvement in Hemoglobin A1c and hypoglycemia reduction over 6–12 months. CGM use in insulin-treated Type 2 diabetes patients also resulted in significant benefits, including reduced variability and fewer severe glucose excursions. Chris:Clinically and economically, CGMs help prevent long-term complications such as cardiovascular disease, nephropathy, and retinopathy. Chris, What patients specifically benefit the most from CGM?Will: CGMs are most commonly indicated for people with Type 1 diabetes and for those with Type 2 diabetes who are using intensive insulin regimens—typically defined as multiple daily injections or insulin pump therapy. Chris:And what are the qualifications in order to be covered by insurance?Will:In the United States, Medicare covers CGM as durable medical equipment for qualifying patients, and coverage requires a prescription, documentation of insulin use, and regular follow-up. Most major private insurers—including Blue Cross, Aetna, UnitedHealthcare, Cigna, and Kaiser—follow similar guidelines. Coverage is generally granted for patients with Type 1 diabetes or insulin-requiring Type 2 diabetes who monitor glucose at least four times daily or use an insulin pump. Chris:Some plans require demonstration of hypoglycemia unawareness or frequent glucose variability. For patients not on insulin, OTC CGMs may be an option, but coverage is typically not provided. That said, new FDA decisions are allowing over-the-counter access to CGMs like Abbott's FreeStyle Libre and Dexcom's Stelo, expanding availability for lifestyle or preventive purposes.Will:[There are a lot of products on the market. Which are the main products and how are they different?]Chris:The three main players in the CGM space are Dexcom, Abbott (FreeStyle Libre), and Senseonics (Eversense), each with unique offerings.Let's start with Dexcom. Dexcom G7 is a real-time CGM system approved for both Type 1 and Type 2 diabetes. It combines a sensor and transmitter into one compact wearable patch worn on the abdomen or upper arm for up to 10 days. It updates glucose readings every 5 minutes and connects directly to a smartphone or Apple Watch via Bluetooth. Dexcom also integrates with insulin pumps like Tandem's t:slim and the Omnipod 5. Data can be shared with providers through Dexcom Clarity, which integrates into electronic medical records (EMRs) like Epic. OTC access is not yet available for DEXCOM G7, but a new non-prescription product called Dexcom Stelo is being rolled out in 2025, targeting non-insulin-using Type 2 patients. Dexcom Stelo will also offer 15-day wear, smartphone integration, and factory calibration. The estimated OTC cost for Dexcom Stelo is expected to be around $99 for a 15-day sensor, or about $198/month.Will:$200! Abbott FreeStyle Libre comes in several versions. The Libre 2 offers 14-day wear and requires users to scan the sensor with their smartphone or reader to retrieve a glucose value. It has optional real-time alarms for high and low readings and transmits data to LibreView, which can integrate with most EMRs. Libre 3 is a real-time CGM with 1-minute interval updates, Bluetooth transmission, and a slimmer profile. Libre sensors are widely used in primary care and available OTC for non-insulin users. Libre 2 sensors cost approximately $70–$85 for a 14-day sensor, while Libre 3 is slightly higher, around $85–$100 per sensor—totaling about $140–$200/month out of pocket without insurance.Chris:Senseonics Eversense E3 is the only implantable CGM on the market. It involves a minor in-office procedure to insert the sensor under the skin of the upper arm, which lasts up to 180 days (and a newer version, Eversense 365, lasts up to one year). A removable transmitter worn on top of the skin sends data every 5 minutes to a mobile app and vibrates for alerts. It requires 1–2 calibrations per day using a traditional fingerstick meter. It integrates with Eversense DMS software for physician monitoring. The total cost for Eversense depends on the insertion procedure and insurance, but cash pay for the full 6-month system is estimated at $2,400–$3,000, or about $400–$500/month including follow-up visits.Will:Additional lower-cost CGMs such as the Medtrum A6 TouchCare are available internationally and in select U.S. pilot programs. These devices offer 14-day wear, smartphone syncing, and daily calibration, but are not yet FDA-approved for wide use and lack full EMR integration.Chris:In terms of performance and value, Dexcom G7 offers the most advanced real-time feedback and integration, making it ideal for those on insulin pumps or needing tight control. Will:FreeStyle Libre offers the best affordability and convenience, especially for non-insulin users or those who prefer not to deal with constant alerts. Eversense offers a niche but compelling option for people who want to avoid frequent sensor changes. Chris, [Are there any downsides or risks that patients should be aware of before trying out CGM?]Chris:CGMs are generally safe and well-tolerated, but they do have limitations. Dexcom G7 has a known failure mode where sensors sometimes fail prematurely, often before the full 10-day duration. Some users have reported “signal loss” errors or random disconnections, especially when switching between phone models or operating systems. There are occasional reports of inaccurate highs or lows due to compression during sleep or dehydration. Though the G7 is factory-calibrated, abrupt changes in hydration or blood flow can affect its readings.Will:FreeStyle Libre systems, particularly Libre 2, require the user to scan the sensor to retrieve data unless alerts are enabled. These devices may be affected by vitamin C (ascorbic acid), which can falsely elevate glucose readings, and they do not currently allow for automated insulin delivery integration. Some Libre 2 users have noted adhesive-related rashes or spontaneous detachment. Libre 3, while more advanced, still may lose Bluetooth connection intermittently, particularly if the phone is out of range or the app is not running in the background.Chris:Senseonics Eversense carries procedural risks due to its implantable nature. Minor scarring or infection at the insertion site has been reported. The transmitter must be worn during waking hours to provide alerts, and users report anxiety over losing the transmitter since data logging is interrupted without it. Calibration is still required, which adds to daily tasks. Additionally, the sensor does not communicate with insulin pumps or closed-loop systems.Will:All CGMs can cause mild skin irritation from adhesive, particularly in users with sensitive skin. Alert fatigue is another consideration, as frequent low- or high-glucose warnings may cause stress or lead users to silence notifications entirely. Finally, relying solely on CGM without periodic fingerstick confirmation in symptomatic scenarios can be a risk, especially during rapid glucose changes.Chris:Conclusion[***] Continuous glucose monitors have reshaped the way we manage diabetes, offering unprecedented insight into glucose trends, diet responses, and insulin timing. While CGMs are not flawless, the technology continues to evolve. Will: If your patient is on insulin or struggling with glucose variability, consider whether CGM is right for your patient. For those not using insulin, consider newer OTC options like FreeStyle Libre or Dexcom Stelo, which offer accessible entry points without the need for prescriptions. As AI integration, longer sensor life, and non-invasive monitoring enter the market, CGM will only become more useful.Dr Arreaza: Personal experience with CGMs. I do not have diabetes, but I have a strong family history of diabetes (including father, 2 grandmas, and about 15 uncles, aunts, and cousins.)I wanted to try it so I could teach my patients about CGM. My first experience was with Freestyle Libre 2: Pros: Painless placement, easy to use, scanning with phone was easier than fingersticks.Cons: Required some assembling to be placed, mild discomfort at night, and nighttime alarms.Dexcom G7:Pros: No need for scanning, feels more stable in your armCons: High readings (had to calibrate for a more accurate reading)Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________References:Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/.

A single cyberattack could cost your practice $10 million, or shut it down completely. That's just one of the threats healthcare providers are facing today, and Long Island plastic surgeon Dr. Mark Epstein is sharing simple ways to protect your practice, from strong passwords and staff training to cloud backups and cyber insurance.Known for being at the forefront of surgical innovation, Dr. Epstein shares his excitement about new, minimally invasive breast augmentation techniques coming soon to the U.S., offering tiny incisions, fewer complications, and lightning-fast recoveries.Add in smart software tools like Nextech and a seamless blend of surgical and non-surgical services under one roof, and it's clear: Dr. Epstein's approach is all about smarter systems and better results. About Mark Epstein, MDDr. Epstein is a dual board-certified plastic surgeon with over 30 years of experience using the most cutting-edge technology and surgical techniques. Dr. Epstein is the inventor of many surgical instruments and stays on the forefront of surgical technology.Learn more about Long Island plastic surgeon Dr. Mark EpsteinFollow Dr. Epstein on Instagram @dr.markepsteinConnect with Dr. Epstein on LinkedInRequest a demo for TouchMDLearn more about Clarity PerformanceGuestMark Epstein, MDEpstein Plastic SurgeryHostTyler Terry, Director of Sales, MedSpaNextechPresented by Nextech, Aesthetically Speaking delves into the world of aesthetic practices, where art meets science, and innovation transforms beauty.With our team of experts we bring you unparalleled insights gained from years of collaborating with thousands of practices ranging from plastic surgery and dermatology to medical spas. Whether you're a seasoned professional or a budding entrepreneur, this podcast is tailored for you.Each episode is a deep dive into the trends, challenges, and triumphs that shape the aesthetic landscape. We'll explore the latest advancements in technology, share success stories, and provide invaluable perspectives that empower you to make informed decisions.Expect candid conversations with industry leaders, trailblazers and visionaries who are redefining the standards of excellence. From innovative treatments to business strategies, we cover it all.Our mission is to be your go-to resource for staying ahead in this ever-evolving field. So if you're passionate about aesthetics, eager to stay ahead of the curve and determined to elevate your practice, subscribe to the Aesthetically Speaking podcast.Let's embark on this transformative journey together where beauty meets business.About NextechIndustry-leading software for dermatology, medical spas, ophthalmology, orthopedics, and plastic surgery at https://www.nextech.com/ Follow Nextech on Instagram @nextechglow

What happens when a health system takes a full-funnel approach to digital transformation? Find out in this episode of Ignite, where Cardinal CEO Alex Membrillo chats with James Morgan, Digital Marketing Manager at Cape Fear Valley Health System. You'll get a behind-the-scenes look at how a fast-growing regional health system rebuilt its website from the ground up, streamlined patient journeys, and tackled online reputation management at scale. You'll hear practical strategies for integrating marketing with EMR systems, optimizing for SEO and AI-driven search, and making the most of limited budgets while supporting rapid clinic expansion. You'll walk away with actionable insights on website transformation, review automation, data-driven decision-making, and the power of keeping communications clear and patient-focused. RELATED RESOURCES Connect with James - https://www.linkedin.com/in/james-morgan-09918478/ Top Healthcare Marketing Strategies & Guide - https://www.cardinaldigitalmarketing.com/healthcare-resources/blog/healthcare-digital-marketing-strategies-tips-ideas/?utm_source=chatgpt.com How to Build a Full-Funnel Healthcare Marketing Strategy - https://www.cardinaldigitalmarketing.com/healthcare-resources/blog/healthcare-full-funnel-marketing-strategy/ What is a Patient Journey? Examples to Grow Your Practice - https://www.cardinaldigitalmarketing.com/healthcare-resources/blog/what-is-a-patient-journey-grow-your-practice/ Harnessing the Power of AI Marketing for Healthcare - https://www.cardinaldigitalmarketing.com/healthcare-resources/blog/harnessing-ai-marketing-for-healthcare/

Kicking off a six-part series on EMR implementation in APAC, this first episode features guests from two Malaysian hospitals sharing lessons and successes from their organizations' decades-long digital transformation journeys. 

TAKEAWAYSMedically, the effects of electromagnetic radiation should interest doctorsPeople must speak out against the encroaching wireless tech being installed everywhereTypical symptoms of EMR exposure include difficulty sleeping, thinking, focusing, and nosebleedsOur homes are full of wireless technology - cut down on the digital devices through choosing wired tech gadgets as much as possible

A wonderful meandering chat with Ketan Badani (Urologist, Mt Sinai, NYC)! We took him for a wine tour in the Yarra Valley, stopping for a pod chat at Rochford Winery about screening for prostate cancer in older men, plus a great tour around Healesviile Sanctuary to introduce Ketan to some Australian wildlife. Then back in Melbourne we had another chat, this time a bit of future-gazing about the future of surgery, and Declan and Ketan trade tales about EMR (that's Electronic Medical Record) delinquency. Ketan was visiting Melbourne as a guest of Device Technologies to speak at the Epworth Healthcare Robotic Urology Masterclass. And what a great guest he was! With your usual hosts Renu Eapen and Declan Murphy. Thanks to our fantastic guide Trish at Healesville Sanctuary, and Beatrice who looked after us at Rochford Winery.This one much better enjoyed on our YouTube channel!Links:Rochford Winery Healesville Sanctuary 

William Sauvé, MD is Chief Medical Officer at Osmind, where he focuses on driving the success of Osmind's nationwide network of 800+ independent psychiatry practices and expanding access to cutting-edge psychiatric care. Dr. Sauvé brings extensive experience in interventional psychiatry, particularly in expanding access to treatments like Transcranial Magnetic Stimulation (TMS) and esketamine. Prior to joining Osmind, he served as Regional Medical Director for Greenbrook TMS NeuroHealth Centers, where he helped grow the organization's network to nearly 200 dedicated interventional psychiatry centers nationwide. His journey in psychiatry began with 11 years of distinguished service as an active-duty Navy psychiatrist. Following his residency, he was deployed to Iraq's Al Anbar Province as the regimental psychiatrist for the 7th Marine Regiment. During his time in the military, he started a procedural psychiatry program that included ECT and patient engagement in post-traumatic stress disorder (PTSD) treatment.  After his military service, he served as Military Clinical Director at Poplar Springs Hospital for three years before founding Virginia Interventional Psychiatry, one of the first interventional psychiatry practices in the Mid-Atlantic region. His practice, dedicated to advancing TMS treatment, was the first practice acquired into what is now Greenbrook TMS NeuroHealth Centers, contributing to their nationwide expansion in providing TMS and esketamine treatments. Dr. Sauvé received his medical degree from the Uniformed Services University of the Health Sciences in Bethesda, Maryland. He completed his residency in adult psychiatry through the National Capital Consortium, which includes the Walter Reed National Military Medical Center, Fort Belvoir Community Hospital, and USUHS. He earned his undergraduate degrees in Biology and Biochemistry from Mercyhurst College in Erie, Pennsylvania. He is certified by the American Board of Psychiatry and Neurology and serves as faculty at the Neuroscience Education Institute. He maintains an active membership in the American Psychiatric Association and the Clinical Transcranial Magnetic Stimulation Society. Website: https://www.osmind.org/ Timestamps: 00:00 Trailer 00:37 Introduction 03:39 Osmind as a comprehensive EMR solution 06:49 Brain stimulation boosts neuroplasticity 11:53 Military vs. academic medical experience 15:12 Weight loss for athletic pursuits 17:33 Reaching full speed safely 19:58 "Carnivorish" diet approach 24:08 Historic orchard ranch's new life 25:53 Rare bear sightings, abundant deer 31:15 Empowering independent mental health practitioners 32:25 Evolving psychiatric treatments 36:35 Pioneering comprehensive psychiatry 40:33 Weight loss without nutrition education 42:53 Where to find Will Join Revero now to regain your health: https://revero.com/YT Revero.com is an online medical clinic for treating chronic diseases with this root-cause approach of nutrition therapy. You can get access to medical providers, personalized nutrition therapy, biomarker tracking, lab testing, ongoing clinical care, and daily coaching. You will also learn everything you need with educational videos, hundreds of recipes, and articles to make this easy for you. Join the Revero team (medical providers, etc): https://revero.com/jobs ‪#Revero #ReveroHealth #shawnbaker  #Carnivorediet #MeatHeals #AnimalBased #ZeroCarb #DietCoach  #FatAdapted #Carnivore #sugarfree Disclaimer: The content on this channel is not medical advice. Please consult your healthcare provider.

Health system IT executives face a persistent strategic dilemma: how to navigate the tension between staying within the core EMR suite and exploring external solutions for critical functions such as patient engagement. This webinar features leaders who will examine the continuous assessment required to determine whether core EMR capabilities are sufficient across specific functionality segments. The conversation will focus on the nuanced process of evaluating emerging niche vendors, identifying meaningful capability gaps, and weighing the operational, governance, and integration implications of stepping outside the suite. Panelists will share how their organizations assess when those gaps in functionality—particularly in patient communication, outreach personalization, and coordination—grow significant enough to justify adopting third-party tools. The discussion will also touch on strategies for managing vendor sprawl, ensuring brand consistency, and maintaining compliance in increasingly complex digital ecosystems. Source: Beyond the EMR? Revisiting Your Strategy Around Patient Engagement & Communications on healthsystemcio.com - healthsystemCIO.com is the sole online-only publication dedicated to exclusively and comprehensively serving the information needs of healthcare CIOs.

Welcome to the Sustainable Clinical Medicine Podcast! In this inspiring episode, Dr. Sarah Smith sits down with Dr. Linde Corrigan, a family physician practicing in Ontario's Ottawa Valley. Dr. Corrigan shares her journey as a rural generalist, juggling family medicine, care of the elderly, and specialized clinic procedures—all while navigating the unique challenges of ADHD within the medical profession. Listen in as Dr. Corrigan opens up about overcoming imposter syndrome, adapting her workflow to suit her learning style, and the tools and reframing strategies that have helped her create a more sustainable clinical day. She and Dr. Smith discuss practical solutions—from using timers and EMR hacks to embracing positive self-talk and gamifying the most dreaded tasks. Whether you're facing your own clinical challenges or just looking for ways to make your workday more manageable, this conversation is packed with actionable insights and relatable stories. Tune in for an honest, uplifting, and strategy-filled episode designed to help you reclaim time for your life outside of medicine! Here are 3 key takeaways from this episode: Make the Most of Your Strengths: Recognizing personal strengths and challenges (like leveraging visual memory or adapting workflows for ADHD) can be a game-changer in both career direction and daily efficiency. Reframe the Hard Parts: Shifting mindset—from “I have to finish this report” to “I'm almost out the door!”—makes a huge difference. Reward yourself, gamify tasks, and see the power of a positive reframe. Gamify for Focus and Flow: Small hacks (timers, shortcut tools like Magical, or breaking tasks into manageable chunks) help combat time blindness and overwhelm, making even inbox management feel like a win. Meet Dr. Linde Corrigan: I am a rural family physician with enhanced certification in care of elderly. Currently, I work part-time in my family medicine practice in Petawawa, as well as part-time at the hospital, as well as in local long-term care homes in the area. I graduated medical school at University of Ottawa in 2010, Family Medicine residency at U of Ottawa in 2014. -------------- Would you like to view a transcript of this episode? Click here ****Get in on the Backlog Buddies Sale where All Session in June are only $10 https://www.backlogbuddies.com/ **** Charting Champions is a premiere, lifetime access Physician only program that is helping Physicians get home with today's work done. All the proven tools, support and community you need to create time for your life outside of medicine. Learn more at https://www.chartingcoach.ca **** Enjoying this podcast? Please share it with someone who would benefit. Also, don't forget to hit “follow” so you get all the new episodes as soon as they are released. **** Come hang out with me on Facebook or Instagram. Follow me @chartingcoach to get more practical tools to help you create sustainable clinical medicine in your life. **** Questions? Comments? Want to share how this podcast has helped you? Shoot me an email at admin@reachcareercoaching.ca. I would love to hear from you.

The Big Unlock Podcast · When Technology Meets Care Management, Outcomes Improve. – Podcast with Rob Posner In this episode, Rob Posner, Chief Technology Officer, AbsoluteCare discusses how the organization is transforming care delivery through a member-centric, value-based model that emphasizes advanced care management and the social determinants of health. Rob explains AbsoluteCare's proactive, longitudinal care management approach – enabled by technology that empowers mobile care teams to engage with members wherever they are, whether at home, in the community, or within hospital settings. He underscores the importance of real-time data access, EMR availability at the point of care, and the role of transitional care managers in ensuring continuity post-discharge. Rob also emphasizes how governance, change management, and attention to operational details such as connectivity, mobility, and privacy are critical to success. Rob also explores AbsoluteCare's innovation strategy, including the use of ambient clinical documentation, AI-driven diabetic retinopathy screening, and organization-wide adoption of Microsoft Copilot. Rob shares his vision for the future of AI agents and robotic process automation to streamline workflows, reduce provider burden, and ultimately improve care outcomes. Take a listen.

The $100K Per Year Clinical Formula In this episode, Dr. Danny Matta breaks down the numbers behind running a lean, profitable lifestyle physical therapy business that nets $100,000/year pre-tax income—with just 15 visits a week.

Send us a textIn this episode we sit down with Alon Joffe, CEO of Israeli AI startup Eleos, for a fascinating deep dive into how behavioral health documentation is being revolutionized. What makes this conversation compelling is learning why Israel has become such a health tech powerhouse - with $1.2 billion in funding in 2024 alone and digital medical records dating back to the 1970s.Alon breaks down how his AI technology reduces clinical documentation time by over 70% for mental health workers dealing with 60-90 minute therapy sessions. The company now serves 20,000 clinicians across 34 states, focusing on the most underserved populations in behavioral health. They explore the stark differences between acute care and behavioral health tech needs, why companies like Epic struggle to cross that divide, and how AI agents are about to transform EMR integration. Plus, Alon shares the dramatic shift from pre-ChatGPT skepticism to today's reality where a quarter of US physicians are already using ambient AI tools.Timestamps:00:00:08 - Introduction and Welcome00:01:02 - Israeli Health Tech Ecosystem and Innovation Culture00:03:51 - Government Healthcare Systems and Innovation Frameworks00:06:09 - Value-Based Care vs Fee-for-Service Risk Models00:09:14 - Introduction to Eleos: Mission and Market Focus00:11:42 - Technology Differentiation and Competitive Landscape00:15:19 - Behavioral Health vs Acute Care System Differences00:16:01 - AI Agents and Job Automation in Healthcare00:18:03 - EMR Integration and the Future of Healthcare Interfaces00:20:12 - Epic's Market Evolution and Platform Strategy00:25:04 - Fundraising Experience and Series C Journey00:27:17 - Technology Evolution: Pre vs Post-ChatGPT Era00:33:53 - Future Plans and Expansion Strategy00:34:57 - Closing Remarks and Final Thoughts

Dr. Nathan Pennell and Dr. Cheryl Czerlanis discuss challenges in lung cancer screening and potential solutions to increase screening rates, including the use of AI to enhance risk prediction and screening processes. Transcript Dr. Nate Pennell: Hello, and welcome to By the Book, a monthly podcast series for ASCO Education that features engaging discussions between editors and authors from the ASCO Educational Book. I'm Dr. Nate Pennell, the co-director of the Cleveland Clinic Lung Cancer Program and vice chair of clinical research for the Taussig Cancer Center. I'm also the editor-in-chief for the ASCO Educational Book.  Lung cancer is one of the leading causes of cancer-related mortality worldwide, and most cases are diagnosed at advanced stages where curative treatment options are limited. On the opposite end, early-stage lung cancers are very curable. If only we could find more patients at that early stage, an approach that has revolutionized survival for other cancer types such as colorectal and breast cancer.  On today's episode, I'm delighted to be joined by Dr. Cheryl Czerlanis, a professor of medicine and thoracic medical oncologist at the University of Wisconsin Carbone Cancer Center, to discuss her article titled, "Broadening the Net: Overcoming Challenges and Embracing Novel Technologies in Lung Cancer Screening." The article was recently published in the ASCO Educational Book and featured in an Education Session at the 2025 ASCO Annual Meeting. Our full disclosures are available in the transcript of this episode.  Cheryl, it's great to have you on the podcast today. Thanks for being here. Dr. Cheryl Czerlanis: Thanks, Nate. It's great to be here with you. Dr. Nate Pennell: So, I'd like to just start by asking you a little bit about the importance of lung cancer screening and what evidence is there that lung cancer screening is beneficial. Dr. Cheryl Czerlanis: Thank you. Lung cancer screening is extremely important because we know that lung cancer survival is closely tied to stage at diagnosis. We have made significant progress in the treatment of lung cancer, especially over the past decade, with the introduction of immunotherapies and targeted therapies based on personalized evaluation of genomic alterations. But the reality is that outside of a lung screening program, most patients with lung cancer present with symptoms related to advanced cancer, where our ability to cure the disease is more limited.  While lung cancer screening has been studied for years, the National Lung Screening Trial, or the NLST, first reported in 2011 a significant reduction in lung cancer deaths through screening. Annual low-dose CT scans were performed in a high-risk population for lung cancer in comparison to chest X-ray. The study population was comprised of asymptomatic persons aged 55 to 74 with a 30-pack-year history of smoking who were either active smokers or had quit within 15 years. The low-dose CT screening was associated with a 20% relative risk reduction in lung cancer-related mortality. A similar magnitude of benefit was also reported in the NELSON trial, which was a large European randomized trial comparing low-dose CT with a control group receiving no screening. Dr. Nate Pennell: So, this led, of course, to approval from CMS (Centers for Medicare and Medicaid Services) for lung cancer screening in the Medicare population, probably about 10 years ago now, I think. And there are now two major trials showing an unequivocal reduction in lung cancer-related mortality and even evidence that it reduces overall mortality with lung cancer screening. But despite this, lung cancer screening rates are very low in the United States. So, first of all, what's going on? Why are we not seeing the kinds of screening rates that we see with mammography and colonoscopy? And what are the barriers to that here? Dr. Cheryl Czerlanis: That's a great question. Thank you, Nate. In the United States, recruitment for lung cancer screening programs has faced numerous challenges, including those related to socioeconomic, cultural, logistical, and even racial disparities. Our current lung cancer screening guidelines are somewhat imprecise and often fail to address differences that we know exist in sex, smoking history, socioeconomic status, and ethnicity. We also see underrepresentation in certain groups, including African Americans and other minorities, and special populations, including individuals with HIV. And even where lung cancer screening is readily available and we have evidence of its efficacy, uptake can be low due to both provider and patient factors. On the provider side, barriers include having insufficient time in a clinic visit for shared decision-making, fear of missed test results, lack of awareness about current guidelines, concerns about cost, potential harms, and evaluating both true and false-positive test results.  And then on the patient side, barriers include concerns about cost, fear of getting a cancer diagnosis, stigma associated with tobacco smoking, and misconceptions about the treatability of lung cancer. Dr. Nate Pennell: I think those last two are really what make lung cancer unique compared to, say, for example, breast cancer, where there really is a public acceptance of the value of mammography and that breast cancer is no one's fault and that it really is embraced as an active way you can take care of yourself by getting your breast cancer screening. Whereas in lung cancer, between the stigma of smoking and the concern that, you know, it's a death sentence, I think we really have some work to be made up, which we'll talk about in a minute about what we can do to help improve this.  Now, that's in the U.S. I think things are probably, I would imagine, even worse when we leave the U.S. and look outside, especially at low- and middle-income countries. Dr. Cheryl Czerlanis: Yes, globally, this issue is even more complex than it is in the United States. Widespread implementation of low-dose CT imaging for lung cancer screening is limited by manpower, infrastructure, and economic constraints. Many low- and middle-income countries even lack sufficient CT machines, trained personnel, and specialized facilities for accurate and timely screenings. Even in urban centers with advanced diagnostic facilities, the high screening and follow-up care costs can limit access. Rural populations face additional barriers, such as geographic inaccessibility of urban centers, transportation costs, language barriers, and mistrust of healthcare systems. In addition, healthcare systems in these regions often prioritize infectious diseases and maternal health, leaving limited room for investments in noncommunicable disease prevention like lung cancer screening. Policymakers often struggle to justify allocating resources to lung cancer screening when immediate healthcare needs remain unmet. Urban-rural disparities exacerbate these challenges, with rural regions frequently lacking the infrastructure and resources to sustain screening programs. Dr. Nate Pennell: Well, it's certainly an intimidating problem to try to reduce these disparities, especially between the U.S. and low- and middle-income countries. So, what are some of the potential solutions, both here in the U.S. and internationally, that we can do to try to increase the rates of lung cancer screening? Dr. Cheryl Czerlanis: The good news is that we can take steps to address these challenges, but a multifaceted approach is needed. Public awareness campaigns focused on the benefits of early detection and dispelling myths about lung cancer screening are essential to improving participation rates. Using risk-prediction models to identify high-risk individuals can increase the efficiency of lung cancer screening programs. Automated follow-up reminders and screening navigators can also ensure timely referrals and reduce delays in diagnosis and treatment. Reducing or subsidizing the cost of low-dose CT scans, especially in low- or middle-income countries, can improve accessibility. Deploying mobile CT scanners can expand access to rural and underserved areas.  On a global scale, integrating lung cancer screening with existing healthcare programs, such as TB or noncommunicable disease initiatives, can enhance resource utilization and program scalability. Implementing lung cancer screening in resource-limited settings requires strategic investment, capacity building, and policy interventions that prioritize equity. Addressing financial constraints, infrastructure gaps, and sociocultural barriers can help overcome existing challenges. By focusing on cost-effective strategies, public awareness, and risk-based eligibility criteria, global efforts can promote equitable access to lung cancer screening and improve outcomes.  Lastly, as part of the medical community, we play an important role in a patient's decision to pursue lung cancer screening. Being up to date with current lung cancer screening recommendations, identifying eligible patients, and encouraging a patient to undergo screening often is the difference-maker. Electronic medical record (EMR) systems and reminders are helpful in this regard, but relationship building and a recommendation from a trusted provider are really essential here. Dr. Nate Pennell: I think that makes a lot of sense. I mean, there are technology improvements. For example, our lung cancer screening program at The Cleveland Clinic, a few years back, we finally started an automated best practice alert in our EMR for patients who met the age and smoking requirements, and it led to a six-fold increase in people referred for screening. But at the same time, there's a difference between just getting this alert and putting in an order for lung cancer screening and actually getting those patients to go and actually do the screening and then follow up on it. And that, of course, requires having that relationship and discussion with the patient so that they trust that you have their best interests. Dr. Cheryl Czerlanis: Exactly. I think that's important. You know, certainly, while technology can aid in bringing patients in, there really is no substitute for trust-building and a personal relationship with a provider. Dr. Nate Pennell: I know that there are probably multiple examples within the U.S. where health systems or programs have put together, I would say, quality improvement projects to try to increase lung cancer screening and working with their community. There's one in particular that you discuss in your paper called the "End Lung Cancer Now" initiative. I wonder if you could take us through that. Dr. Cheryl Czerlanis: Absolutely. "End Lung Cancer Now" is an initiative at the Indiana University Simon Comprehensive Cancer Center that has the vision to end suffering and death from lung cancer in Indiana through education and community empowerment. We discuss this as a paradigm for how community engagement is important in building and scaling a lung cancer screening program.  In 2023, the "End Lung Cancer Now" team decided to focus its efforts on scaling and transforming lung cancer screening rates in Indiana. They developed a task force with 26 experts in various fields, including radiology, pulmonary medicine, thoracic surgery, public health, and advocacy groups. The result of this work is an 85-page blueprint with key recommendations that any system and community can use to scale lung cancer screening efforts. After building strong infrastructure for lung cancer screening at Indiana University, they sought to understand what the priorities, resources, and challenges in their communities were. To do this, they forged strong partnerships with both local and national organizations, including the American Lung Association, American Cancer Society, and others. In the first year, they actually tripled the number of screening low-dose CTs performed in their academic center and saw a 40% increase system-wide. One thing that I think is the most striking is that through their community outreach, they learned that most people prefer to get medical care close to home within their own communities. Establishing a way to support the local infrastructure to provide care became far more important than recruiting patients to their larger system.  In exciting news, "End Lung Cancer Now" has partnered with the IU Simon Comprehensive Cancer Center and IU Health to launch Indiana's first and only mobile lung screening program in March of 2025. This mobile program travels around the state to counties where the highest incidence of lung cancer exists and there is limited access to screening. The mobile unit parks at trusted sites within communities and works in partnership, not competition, with local health clinics and facilities to screen high-risk populations. Dr. Nate Pennell: I think that sounds like a great idea. Screening is such an important thing that it doesn't necessarily have to be owned by any one particular health system for their patients. I think. And I love the idea of bringing the screening to patients where they are. I can speak to working in a regional healthcare system with a main campus in the downtown that patients absolutely hate having to come here from even 30 or 40 minutes away, and they'd much rather get their care locally. So that makes perfect sense.  So, under the current guidelines, there are certainly things that we can do to try to improve capturing the people that meet those. But are those guidelines actually capturing enough patients with lung cancer to make a difference? There certainly are proposals within patient advocacy communities and even other countries where there's a large percentage of non-smokers who perhaps get lung cancer. Can we expand beyond just older, current and heavy smokers to identify at-risk populations who could benefit from screening? Dr. Cheryl Czerlanis: Yes, I think we can, and it's certainly an active area of research interest. We know that tobacco is the leading cause of lung cancer worldwide. However, other risk factors include secondhand smoke, family history, exposure to environmental carcinogens, and pulmonary diseases like COPD and interstitial lung disease. Despite these known associations, the benefit of lung cancer screening is less well elucidated in never-smokers and those at risk of developing lung cancer because of family history or other risk factors. We know that the eligibility criteria associated with our current screening guidelines focus on age and smoking history and may miss more than 50% of lung cancers. Globally, 10% to 25% of lung cancer cases occur in never-smokers. And in certain parts of the world, like you mentioned, Nate, such as East Asia, many lung cancers are diagnosed in never-smokers, especially in women. Risk-prediction models use specific risk factors for lung cancer to enhance individual selection for screening, although they have historically focused on current or former smokers.  We know that individuals with family members affected by lung cancer have an increased risk of developing the disease. To this end, several large-scale, single-arm prospective studies in Asia have evaluated broadening screening criteria to never-smokers, with or without additional risk factors. One such study, the Taiwan Lung Cancer Screening in Never-Smoker Trial, was a multicenter prospective cohort study at 17 medical centers in Taiwan. The primary outcome of the TALENT trial was lung cancer detection rate. Eligible patients aged 55 to 75 had either never smoked or had a light and remote smoking history. In addition, inclusion required one or more of the following risk factors: family history of lung cancer, passive smoke exposure, history of TB or COPD, a high cooking index, which is a metric that quantifies exposure to cooking fumes, or a history of cooking without ventilation. Participants underwent low-dose CT screening at baseline, then annually for 2 years, and then every 2 years for up to 6 years. The lung cancer detection rate was 2.6%, which was higher than that reported in the NLST and NELSON trials, and most were stage 0 or I cancers. Subsequently, this led to the Taiwan Early Detection Program for Lung Cancer, a national screening program that was launched in 2022, targeting 2 screening populations: individuals with a heavy history of smoking and individuals with a family history of lung cancer.  We really need randomized controlled trials to determine the true rates of overdiagnosis or finding cancers that would not lead to morbidity or mortality in persons who are diagnosed, and to establish whether the high lung detection rates are associated with a decrease in lung cancer-related mortality in these populations. However, the implementation of randomized controlled low-dose CT screening trials in never-smokers has been limited by the need for large sample sizes, lengthy follow-up, and cost.  In another group potentially at higher risk for developing lung cancer, the role of lung cancer screening in individuals who harbor germline pathogenic variants associated with lung cancer also needs to be explored further. Dr. Nate Pennell: We had this discussion when the first criteria came out because there have always been risk-based calculators for lung cancer that certainly incorporate smoking but other factors as well and have discussion about whether we should be screening people based on their risk and not just based on discrete criteria such as smoking. But of course, the insurance coverage for screening, you have to fit the actual criteria, which is very constrained by age and smoking history. Do you think in the U.S. there's hope for broadening our screening beyond NLST and NELSON criteria? Dr. Cheryl Czerlanis: I do think at some point there is hope for broadening the criteria beyond smoking history and age, beyond the criteria that we have typically used and that is covered by insurance. I do think it will take some work to perhaps make the prediction models more precise or to really understand who can benefit. We certainly know that there are many patients who develop lung cancer without a history of smoking or without family history, and it would be great if we could diagnose more patients with lung cancer at an earlier stage. I think this will really count on there being some work towards trying to figure out what would be the best population for screening, what risk factors to look for, perhaps using some new technologies that may help us to predict who is at risk for developing lung cancer, and trying to increase the group that we study to try and find these early-stage lung cancers that can be cured. Dr. Nate Pennell: Part of the reason we, of course, try to enrich our population is screening works better when you have a higher pretest probability of actually having cancer. And part of that also is that our technology is not that great. You know, even in high-risk patients who have CT scans that are positive for a screen, we know that the vast majority of those patients with lung nodules actually don't have lung cancer. And so you have to follow them, you have to use various models to see, you know, what the risk, even in the setting of a positive screen, is of having lung cancer.  So, why don't we talk about some newer tools that we might use to help improve lung cancer screening? And one of the things that everyone is super excited about, of course, is artificial intelligence. Are there AI technologies that are helping out in early detection in lung cancer screening? Dr. Cheryl Czerlanis: Yes, that's a great question. We know that predicting who's at risk for lung cancer is challenging for the reasons that we talked about, knowing that there are many risk factors beyond smoking and age that are hard to quantify. Artificial intelligence is a tool that can help refine screening criteria and really expand screening access. Machine learning is a form of AI technology that is adept at recognizing patterns in large datasets and then applying the learning to new datasets. Several machine learning models have been developed for risk stratification and early detection of lung cancer on imaging, both with and without blood-based biomarkers. This type of technology is very promising and can serve as a tool that helps to select individuals for screening by predicting who is likely to develop lung cancer in the future.  A group at Massachusetts General Hospital, represented in our group for this paper by my co-authors, Drs. Fintelmann and Chang, developed Sybil, which is an open-access 3D convolutional neural network that predicts an individual's future risk of lung cancer based on the analysis of a single low-dose CT without the need for human annotation or other clinical inputs. Sybil and other machine learning models have tremendous potential for precision lung cancer screening, even, and perhaps especially, in settings where expert image interpretation is unavailable. They could support risk-adapted screening schedules, such as varying the frequency and interval of low-dose CT scans according to individual risk and potentially expand lung cancer screening eligibility beyond age and smoking history. Their group predicts that AI tools like Sybil will play a major role in decoding the complex landscape of lung cancer risk factors, enabling us to extend life-saving lung cancer screening to all who are at risk. Dr. Nate Pennell: I think that that would certainly be welcome. And as AI is working its way into pretty much every aspect of life, including medical care, I think it's certainly promising that it can improve on our existing technology.  We don't have to spend a lot of time on this because I know it's a little out of scope for what you covered in your paper, but I'm sure our listeners are curious about your thoughts on the use of other types of testing beyond CT screening for detecting lung cancer. I know that there are a number of investigational and even commercially available blood tests, for example, for detection of lung cancer, or even the so-called multi-cancer detection blood tests that are now being offered, although not necessarily being covered by insurance, for multiple types of cancer, but lung cancer being a common cancer is included in that. So, what do you think? Dr. Cheryl Czerlanis: Yes, like you mentioned, there are novel bioassays such as blood-based biomarker testing that evaluate for DNA, RNA, and circulating tumor cells that are both promising and under active investigation for lung cancer and multi-cancer detection. We know that such biomarker assays may be useful in both identifying lung cancers but also in identifying patients with a high-risk result who should undergo lung cancer screening by conventional methods. Dr. Nate Pennell: Anything that will improve on our rate of screening, I think, will be welcome. I think probably in the future, it will be some combination of better risk prediction and better interpretation of screening results, whether those be imaging or some combination of imaging and biomarkers, breath-based, blood-based. There's so much going on that it is pretty exciting, but we're still going to have to overcome the stigma and lack of public support for lung cancer screening if we're going to move the needle. Dr. Cheryl Czerlanis: Yes, I think moving the needle is so important because we know lung cancer is still a very morbid disease, and our ability to cure patients is not where we would like it to be. But I do believe there's hope. There are a lot of motivated individuals and groups who are passionate about lung cancer screening, like myself and my co-authors, and we're just happy to be able to share some ways that we can overcome the challenges and really try and make an impact in the lives of our patients. Dr. Nate Pennell: Well, thank you, Dr. Czerlanis, for joining me on the By the Book Podcast today and for all of your work to advance care for patients with lung cancer. Dr. Cheryl Czerlanis: Thank you, Dr. Pennell. It's such a pleasure to be with you today. Thank you. Dr. Nate Pennell: And thank you to our listeners for joining us today. You'll find a link to Dr. Czerlanis' article in the transcript of this episode.  Please join us again next month for By the Book's next episode and more insightful views on topics you'll be hearing at the education sessions from ASCO meetings throughout the year, and our deep dives on approaches that are shaping modern oncology. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:     Dr. Nathan Pennell    @n8pennell   @n8pennell.bsky.social Dr. Cheryl Czerlanis Follow ASCO on social media:     @ASCO on X (formerly Twitter)     ASCO on Bluesky    ASCO on Facebook     ASCO on LinkedIn     Disclosures:    Dr. Nate Pennell:        Consulting or Advisory Role: AstraZeneca, Lilly, Cota Healthcare, Merck, Bristol-Myers Squibb, Genentech, Amgen, G1 Therapeutics, Pfizer, Boehringer Ingelheim, Viosera, Xencor, Mirati Therapeutics, Janssen Oncology, Sanofi/Regeneron       Research Funding (Institution): Genentech, AstraZeneca, Merck, Loxo, Altor BioScience, Spectrum Pharmaceuticals, Bristol-Myers Squibb, Jounce Therapeutics, Mirati Therapeutics, Heat Biologics, WindMIL, Sanofi    Dr. Cheryl Czerlanis: Research Funding (Institution): LungLife AI, AstraZeneca, Summit Therapeutics

Discover how Mental Health Cooperative (MHC) in Nashville transformed their behavioral health care delivery with the eClinicalWorks 24-hour care module. In this episode, we welcome Megan Isham, Senior Clinical Systems Manager at MHC, who shares their transformative journey and the impact of this tool on their operations. With the growing recognition of behavioral and mental health, it's crucial to understand that delivering mental healthcare involves a broad spectrum of services. From outpatient therapy and counselling to crisis management, detox, and residential programs, each service comes with unique requirements. This podcast dives into how MHC has leveraged these capabilities to enhance their service delivery and improve health outcomes. Megan details how the Behavioral Health (BH) module has streamlined workflows, integrated care episodes, and customized protocols to meet the specific needs of their diverse patient population. She explains how the system's web-based nature allows their field staff to access vital tools in real time, significantly increasing efficiency and care quality. Key highlights include the seamless integration with Pyxis™ for medication management, customizable Progress Notes, and specialized order sets that cater to both inpatient and outpatient needs. Megan also discusses the innovative approaches to patient safety and the efficient management of complex cases through electronic safety plans and real-time census tracking. This episode is packed with valuable insights into how MHC's adoption of the BH module has been a game changer, delivering comprehensive services that truly made a difference.

If you're a physician with at least 5 years of experience looking for a flexible, non-clinical, part-time medical-legal consulting role… ...Dr. Armin Feldman's Medical Legal Coaching program will guarantee to add $100K in additional income within 12 months without doing any expert witness work. Any doctor in any specialty can do this work. And if you don't reach that number, he'll work with you for free until you do, guaranteed. How can he make such a bold claim? It's simple, he gets results…  Dr. David exceeded his clinical income without sacrificing time in his full-time position. Dr. Anke retired from her practice while generating the same monthly consulting income.  And Dr. Elliott added meaningful consulting work without lowering his clinical income or job satisfaction. So, if you're a physician with 5+ years of experience and you want to find out exactly how to add $100K in additional consulting income in just 12 months, go to arminfeldman.com.                                                          =============== Learn the business and management skills you need by enrolling in the University of Tennessee Physician Executive MBA program at nonclinicalphysicians.com/physicianmba. Get the FREE GUIDE to 10 Nonclinical Careers at nonclinicalphysicians.com/freeguide. Get a list of 70 nontraditional jobs at nonclinicalphysicians.com/70jobs.                                                                                                 =============== In this continuation of the conversation with Dr. Josh Umbehr, the focus shifts to how his 15 years in membership-based care have led to innovations beyond the traditional Direct Primary Care model. He shares how the success of his practice inspired the creation of Atlas MD's electronic medical record system, designed specifically for direct care practices. Unlike traditional systems overloaded with insurance-driven features, this EMR streamlines clinical work by removing unnecessary administrative functions. He also introduces his latest venture, Not Health Insurance, a fixed indemnity plan designed to complement DPC by covering major medical costs like hospitalizations, cancer treatment, and emergency procedures. Unlike ACA plans, this model returns money directly to patients and takes advantage of significant uninsured discounts from hospitals that often go unnoticed. By removing insurance barriers from routine care while still providing support for serious medical needs, this approach creates a more efficient and accessible healthcare experience. It also addresses common concerns about physician access and system sustainability, offering a model that prioritizes both patient outcomes and professional satisfaction. You'll find links mentioned in the episode at  nonclinicalphysicians.com/thrive-with-direct-primary-care/

In this episode of the Becker's Healthcare Podcast, Erica Carbajal sits down with Jose Arnold Tariga, Director of Clinical Education and Development at Insight Global Health, to explore the hidden pitfalls in integrating internationally educated nurses (IENs) into U.S. health systems. Arnold shares best practices including pre-arrival preparation, EMR training, and simulation-based education, emphasizing that successful IEN programs require holistic support—not just clinical onboarding. Tune in to learn why organizational alignment, cultural humility, and early investment are key to building a resilient, diverse nursing workforce.This episode is sponsored by Insight Global Health.

Chris Boyer and Reed Smith explore how traditional performance marketing tactics have unraveled — and what must replace them. From cookie deprecation to HIPAA compliance and signal loss across Meta and Google, the rules have changed. But the need for results hasn't. They discuss: Why platform-optimized media is no longer reliable How privacy and regulatory shifts are redefining performance marketing The rise of media mix modeling and infrastructure-led strategy What modern measurement looks like when attribution pixels disappear Aaron Burnett, CEO of Wheelhouse DMG, joins to share how his team rebuilt performance marketing around privacy-first data, internal measurement models, and transparent media planning. He breaks down the critical difference between CDPs and data warehouses, the real-world challenge of earning trust to access EMR data, and how AI is reshaping execution without replacing strategy. Mentions from the Show:  Aaron Burnett on LinkedIn WheelhouseDMG Digital Clinic podcast Reed Smith on LinkedIn Chris Boyer on LinkedIn Chris Boyer website Chris Boyer on BlueSky Reed Smith on BlueSky Learn more about your ad choices. Visit megaphone.fm/adchoices

Thiersch, JD, speaks with Alex Lirtsman, founder and CEO of CorralData, to explore how medical spas can unlock real-time, HIPAA-compliant insights without changing their existing systems. CorralData integrates everything from your EMR to marketing, payroll, and finance systems, giving med spas the ability to uncover actionable insights that drive profitability, patient retention, and scalable growth. Listen for strategies to ask smarter questions of your data, including: Integrating all of your existing platforms to get actionable insights from your data; How multi-location practices, med spa rollups and private equity develop playbooks; Navigating HIPAA and BAAs with AI companies to create secure data analysis tools; Using reverse ETL to optimize for high lifetime value patients and boost profitability; The questions you can ask your data with conversational AI and large language models; CorralData's tailor-made solutions for Advanced MedAesthetic Partners, and more! -- Music by Ghost Score

Dr. Luis Raez and Michael Reff share the newest update to the medically integrated dispensing pharmacy standards from NCODA and ASCO. They review updates to domain one, on key patient-centered quality standards on health equity and social determinants of health, drug access, patient safety, education, and adherence to maximize treatment outcomes and domain two, on key operational quality standards on logistics, care coordination, and waste prevention. We also cover the impact of these updated standards for clinicians, oncology practices, and people receiving oral anti-cancer medications. Read the complete standards, “Medically Integrated Dispensing Pharmacy: ASCO-NCODA Standards.” Transcript These standards, clinical tools, and resources are available on ASCO.org.  Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the JCO Oncology Practice. Brittany Harvey: Hello, and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts.  My name is Brittany Harvey, and today I'm interviewing Michael Reff from the Network of Collaborative Oncology Development and Advancement and Dr. Luis Raez from Memorial Cancer Institute and Florida Atlantic University, co-chairs on "Medically Integrated Dispensing Pharmacy: American Society of Clinical Oncology – Network of Collaborative Oncology Development and Advancement Association Standards Update." Thank you for being here, Michael and Dr. Raez. Dr. Luis Raez: Thanks for inviting us. Michael Reff: Thank you for having us. Brittany Harvey: Then, before we discuss these standards, I'd like to note that ASCO takes great care in the development of its standards and ensuring that the ASCO Conflict of Interest policy is followed for each guidance product. The disclosures of potential conflicts of interest for the expert panel, including Michael and Dr. Luis Raez who have joined us here today, are available online with the publication of the standards in JCO Oncology Practice, which is linked in the show notes. So then, to dive into the content here, Michael, I'd like to start with what prompted an update to these ASCO-NCODA standards and what is the scope of this update? Michael Reff: Thank you, Brittany. What led NCODA and ASCO to endeavor in this, and it started back in 2019 as the amount of oral anticancer medications became more and more prevalent in cancer treatment, we saw the need providing a blueprint for excellence in care for patients prescribed oral anticancer medications, specifically in the outpatient setting. And the update was driven by the rapid growth of these oral oncolytics starting back in the mid to late 2015 through 2019 or so, and then continued on into the 2020s where we are today. We saw the increase in the complexity of the management of these patients with these therapies basically outside the traditional clinical settings. And we wanted to make sure that with more cancer treatments that are taken at home than just at the clinic, like in the oral setting, new challenges had emerged around patient safety, access, adherence, and overall treatment success. The updates now address patient-centered and operational interventions designed to improve access, safety, quality, accountability, and outcomes of oral anticancer and other supportive care medications prescribed for the cancer patient. Dr. Luis Raez: As Mike said, these guidelines help improve patient care tremendously, but also help us a lot as an oncologist, you know, community oncologists that- now that we have opportunity to dispense these oral oncolytics, we need help to create our medical integrated pharmacies, and NCODA is providing here a way that, how to do this safely, efficaciously, good quality, you know? So that's why I think we always do everything for the patients, but also this helps a lot to the doctors. And there are a lot of what we call specialty pharmacies or medical integrated pharmacies now nationwide. Michael Reff: I'll build on what Dr. Raez had mentioned. This is the impetus. If you looked at the innovation that was coming from the pharmaceutical companies, many of it coming in the oral form for anticancer medications, and based on that, taking a look at the infrastructure that is in place in these practices, whether it's in the community or the IDN or health system settings, this amount of innovation that was coming needed to be addressed by taking a look at the medically integrated oncology team. And these standards address not just the pharmacy component, but also the whole continuum of care, starting with a medical oncologist or the hematologist, with the pharmacists, nurses, the pharmacy technicians, others that are involved in the care of the patient. And there were no standards involved. And when we approached ASCO back in 2018 to eventually publish the first version of these standards, the need was identified, and we worked collaboratively with ASCO to create the first set and then the revisions as we talked about. One thing to note regarding the revision plus the original standards, we had a cross-section of the care team on the committee, and we did that very purposefully. So, the ASCO-NCODA team curated a committee to help develop these original standards and the revision of these standards with medical oncologists both from community and health systems, pharmacists from both community and health systems, and also nurses. And we also included a patient that currently has and currently receives oral anticancer medication. And so NCODA and ASCO are very proud of the committee that we put together because of the experts in their field, but also extended the invitation to a current patient. And we embedded everybody's expertise in the curation of these standards. Brittany Harvey: Absolutely. I appreciate that background and context and how it's critical to improve patient care. And these standards really help oncologists, and we're looking across the continuum of care to provide optimal care for our patients. So then next, Dr. Raez, I'd like to review the key points of the revised standards for our listeners. So for Domain 1, what are the key patient-centered quality standards on health equity and social determinants of health, drug access, patient safety, education, and adherence to maximize treatment outcomes? Dr. Luis Raez: Yeah, this was a great effort, you know, at the multidisciplinary team. And as you can read in the standard, there were more than 240 publications reviewed; more than 55 of them are quoted here. And the standards are in two groups, as you said. With the group one, I'll briefly mention some of them. For example, SDOH, social determinants of health, is very important because as doctors, we prescribe, and sometimes patients don't get the medication, you know? And we prescribe assuming that 100% of the patients will get the medication. But something simple like the patient doesn't have insurance, the patient is underinsured. I have a patient that we didn't have an address to send the medication because he's homeless. Something that as a doctor you say, "Oh, oh my God, this is outside my realm," but it's not outside reality. So that's why, even if we don't think that this is part of our expertise dealing with social determinants of health, the fact that the patients have food insecurity, they don't have transportation, they don't have insurance, they don't have a caregiver, impact tremendously in the outcomes of the therapy. So that's why, basically, in this standard, we want to call attention that SDOH, social determinants of health, needs to be identified. There are in the literature countless examples of why this is important. For example, in the guidelines, we quote two or three examples of prostate cancer studies that, for example, we quote a study of 27,000 people with prostate cancer that were taking oral oncolytics, and how come the fact that the elderly, seniors, the fact that they have high prescription costs, and how all of this affected the adherence to the medication. And that's why it's important to identify the SDOH. And in other sections of the guidelines, we said how to address them, no? Another important thing in this domain is the cultural, you know, we need to be culturally sensitive and to take care of all of these social factors. For example, here in South Florida, we deal with the Haitian culture, Filipino culture, Latin culture, and American culture, and it's a blend, but it's not easy to go from one to the other. Another one is the fact that we have to include new technologies. A lot of patients, for example, we use EMR, EMR Epic, and now Epic has everything in the phone. The fact that we can have now the patient can see her prescription medication over the phone, the fact that they can use the phone to request from you a refill, and from your phone, you send the refill to the pharmacy, and you notify from your phone to the patient that the refill is sent, and the patient can check in his phone that the refill is ready. These things are amazing because that's why it's important that we incorporate these technologies to the patient care, and in this specific case, of dispensation of oral therapies, no? Another crucial point is education. You cannot be sending a patient a package of 300 pills without education. So that's why in our guidelines, mainly pharmacy, clinical pharmacies, or in some centers like mine, we have advanced practice providers, it's mandatory in our centers to have like a one hour of education before you send the prescription. So the patient is aware about side effects and contraindications, all of these things. They provide them also materials and also consent. You know, in the old times, you don't give chemo without a consent. Now, a lot of people say, "Oh, it's only a pill." There is a lot of benefits or side effects that can come from the pill, so you need to consent everybody, you know? So, another aspect is adherence. I already told about that, but we need to provide patients with a baseline assessment, no? So, you cannot send again the prescription and hope, "Oh, I'll figure it out what happened next month when the patient comes back." I tell you, the patient is homeless, where are you going to send it? If the patient is telling you, "I don't have insurance," what good is it for you to send a prescription? The patient will not get it. So that's why you need to do a baseline assessment of adherence. You need to do a calendar. You need to do electronic support, I mentioned already with the EMR and the phones. For example, my MIP, my specialty pharmacist, sends me a message in the EMR, "Dr. Raez, the insurance is not covering, the patient has a high copayment, we are going to delay the dispensation of the medication." So there needs to be a communication. Or sometimes there is a confusion with the insurance, and I cannot wait for the poor patient to call three, four weeks later, "Oh, I didn't get the medication," to know what happened, no? My MIP is very good. They send the clinical pharmacist a message, "Hey, you know, the insurance doesn't believe that the pill is adequate, or you need to provide more documentation. You need to prove the mutation, the genetic aberration." So if you provide us that, the insurance may approve. So that communication with the doctor is very important to improve adherence. And one important thing that we have in this one that we didn't have in the anterior is the tracking of outside medications. A lot of times you say, "Okay, the insurance allowed us to provide the medication it's 100% responsible." But then the insurance says, "Oh, no, no, don't worry. CVS will provide the medication." So it says, "Well, it's you know, it's not my responsibility. CVS will provide the medication, they have to take care." But we know that outside our specialty pharmacies or MIPs, the care is not very good. So that's why we are taking our ownership that, "Okay, the insurance said the patient will get the medication from some outside pharmacy." But our clinical pharmacists track that. What happened? Did the patient get it? The patient didn't get it. The copayment is still high. So even if you get the medication from somewhere else, if the copayment is high, we, our clinical pharmacists, help the patient to navigate and get the foundation or the copayment or finally the maker, the industry partner, provides the drug for free, but somebody needs to do the paperwork. And that's why this is very important. We cannot abort our responsibility because, "Oh, the insurance said somebody else will give it." I work for the public healthcare system, so my patients, some of them don't have insurance, they are underinsured. So we see these problems every day. And finally, the standards talk about the importance of safety, documentation, verification, monitoring, refills, you know, you need to keep track of refills. We already mentioned how important is the technology to facilitate the refills, and the quality. Brittany Harvey: Yes, thank you for touching on those highlights for Domain 1. It's important that all patients have access to care and these oral anticancer medications, and not only just access to care, but safe and effective care. It's really important, as you mentioned, Dr. Raez, to meet patients where they're at and incorporate technology. And I also want to note the coordination with external pharmacies that you mentioned in tracking outside medications as well. It's not only important for multidisciplinary care within the oncology practice itself, but also external to the oncology practice. That's why we put together this multidisciplinary panel to develop these standards. So then, expanding on that, Dr. Raez, for Domain 2, what are the key operational quality standards? Those on logistics, care coordination, and waste prevention. Dr. Luis Raez: Yeah, we have a lot of standards here, but maybe we can summarize in five or six points, no? For example, financial toxicity in cost and waste are very important because the patients, yeah, you put them on therapy, but as you can understand, if there is disease progression, the patient don't need the medications. And sometimes you get refills even if the patient has disease progression. If you do a dose reduction, the same problem. Or you discontinue medication and the patient keeps getting the drugs. So, you're talking about drugs that are between 20 and 30 thousand dollars per month. This is a lot of money. There are studies that we're quoting in the standards that the waste could be from 1 to 3 or 4 thousand per patient, no? Another aspect is dispensing. When you dispense the medication, this is not as easy as, "I'll ship to your house a bag of medications." You know, there needs to be a diagram, a decision tree. You need to train the staff to know what we're doing. There needs to be an auditing of the process. They need to be even packaging and shipping, you know? For example, I'm in Florida today and outside in summer it's going to be 95 degrees. So, everybody leaves the package outside your house, and sometimes you go the whole day until when you come at 6:00 p.m. There are medications that cannot be left outside there, you know? I don't know, it sounds like a joke, but I have a patient that the medication used to be stolen because people thought that that was something important, you know? And of course, it's important because it's a $20,000 medication. So, the poor patient, because he lives in an area that is not safe, has to come and pick up in person. All of these things sound very trivial, but that's real life that affects adherence. Another important thing is shortage. This is something that we just suffered two or three years ago, and we have to think about what happens in the next shortage. What happens if there's going to be a shortage? What do we do or how are we going to do that? Now we know it's something that is happening probably very soon again, and something that we have to consider. Another standard is the care coordination. You need to have probably, if it's possible, a coordinator. I know that for small practices it's very hard, but for big cancer centers, you should have a coordinator of this. I already mentioned before, the communication between the physicians and the doctors to coordinate the care, no? You need to write the prescription again, you need to provide more information, or to be notified, "Hey, you know, the patient is throwing up in the first week, you need to see the patient, please," no? So, this type of communication needs to exist so we can serve the patient better. It's also important, you know, we're improving quality and we're improving care. It's important to try to collect patient-reported outcomes. This is something that now we have the opportunity, if we do things well, to do it and show that we're providing a better care. The other thing is that we already mentioned SDOH in the other standard. In this standard, we mention mainly SDOH to partner. For example, we collect in my center SDOH, and I always get frustrated when the patient doesn't have transportation. But I didn't know that there are local institutions that provide free Uber rides, free Lyft rides. So that's why it's important to partner with these institutions. I have a local grocery chain that provides free food for the patients, and I didn't know that. It's important to be aware what the patient needs and what resources do you have to fulfill the SDOH. That's the part that we mention in here. So that's why, in summary, those are the six probably most important points here. I'll ask Mike for some comments. Michael Reff: Thank you, Dr. Raez. Brittany, to answer your question, and as was pointed out on logistics, care coordination, and prevention of waste, certainly that is an aspect that has changed in the revision that we're here to talk about. There's really two components to waste, and it's cost avoidance and then waste prevention. And as Dr. Raez mentioned several times, the importance of the medically integrated team and having the ability for that practice to fill that prescription internally and have robust documentation. Cost avoidance is a critical component that the medically integrated pharmacy, or the MIP, can help the total cost of care. And that is by preventing errant fills or waste that can occur by intervening in the care of the cancer patient, as we do every day. But when the practice has access to the medication and can fill that prescription in-house in the medically integrated pharmacy, that team, that care coordination that takes place, can prevent those errant fills or additional fills when there's dose reductions, there's holidays, there's things that happen in real time. And it's impossible for a mail-order pharmacy that's in another state that has lead times, when a prescription needs to be mailed 7 days or 10 days before the patient will run out of the medication, it's impossible for them to logistically coordinate that care like we can internally within the medically integrated pharmacy. So, we prevent waste and overall cost of care by cost avoidance and having that coordination or that continuity of care that we talk about. And we prevent waste from the mail-order pharmacies by taking that prescription internally and filling it, but also doing it in a way that's more sustainable and cost-effective for all stakeholders in the oncology ecosystem. Brittany Harvey: Absolutely. Thank you both for reviewing those key standards for Domain 2 and touching on the importance of distribution logistics and all the things that a medically integrated pharmacy needs to think through in getting oral anticancer agents to patients. Following that, Michael, we've touched on this a little bit earlier, but how will these updated standards impact clinicians and oncology practices? Michael Reff: Yes, and as Dr. Raez and I have discussed throughout this podcast, these additional standards are there to help support that continuity of care by educating the clinicians that are in the oral anticancer medication space to elevate their provision for these oral therapies. What I mean by that is the practice has to perform at a certain level in order for them to, as I call it, deserve the right to fill that prescription by having the processes and procedures in place. And these standards, these updated or revised standards, are the blueprint for better patient care and to help the practices execute on that journey of continuous improvement. Dr. Luis Raez: Yeah, I only want to add, we have practical examples in the guidelines. We quote a couple of studies that have been successful. And this year, for example, I am a lung cancer doctor, we are presenting in World Lung our standards of adherence to oral oncolytics for EGFR therapy, following the NCODA-ASCO standards. We're around 95% of adherence. We are a healthcare system that is public. We have people with no insurance and a lot of social determinants of health. We are trying to show that it's feasible, even in the most difficult circumstance, when you follow the standards, to be successful. Brittany Harvey: Definitely, these standards can help clinicians and oncology practices succeed in providing these medications. So then beyond that, and to wrap us up, Michael, what do these revised standards mean for patients who are receiving oral anticancer medications? Michael Reff: Yes, great point and question, Brittany, because we have covered the benefits to the clinicians and the practices themselves. But how is this going to support better patient care? And it does it in a whole host of ways. I'll cover just a few of them. What I'm about to share with you relates back to what we call at NCODA the "core claims." Like, what's the core claims of having a medically integrated pharmacy within the practice? And there are seven different core claims that we feel practices that are focused on the continuity of care can deliver better outcomes that are embedded in these standards. And it's talking about abandonment, adherence, access and affordability, speed to therapy or time to fill, as we call it, education, patient satisfaction, and cost avoidance that we covered earlier. So those are the core claims that a practice that follows these revised standards can help elevate. So, faster and more affordable access to the oral cancer medications; individualized support to address barriers like transportation, finance, language, or health literacy, and so on; clear, patient-friendly education; something that is near and dear to all clinicians' hearts, and of course, the patient that was on our panel or on our committee, to empower them to manage side effects and recognize when to seek help; and a stronger partnership with a care team, with regular follow-ups focused on their experience, challenges, and successes; and then, greater overall safety through proactive monitoring for medication errors or complications. So all of these aspects, or tenets, as I'll call them, are baked into these quality standards that are totally aligned with NCODA's core claims document that, again, talks about abandonment, adherence, access and affordability, speed to therapy, education, satisfaction for the patients, and also cost avoidance. Dr. Luis Raez: I only want to add and invite the community to adhere to these standards, to practice the standards. You will be providing the best patient care that we can nowadays. Brittany Harvey: Definitely. I think these standards are very important. And Michael, I thank you for touching on those key claims from NCODA. I think those, along with these updated standards, will improve outcomes for patients everywhere. So I want to thank you both so much for your work to update these standards and all the time you put into it. And thank you for your time today too, Michael and Dr. Raez. Michael Reff: I'd like to thank not only the committee, my esteemed committee that helped support the standards and the revision. Many of the original healthcare providers and patient that were on the first go of the standards were part of the second standards. We revised it, of course, and we got additional support from the new committee. And certainly ASCO and their partnership and collaboration with NCODA has been tremendous. And we look forward to the oncology community at large adopting these standards, again, to work together, we do become stronger, and it will improve cancer care for patients receiving oral anticancer medications. So thank you, Brittany. Dr. Luis Raez: I only want to say the same thing. Actually, there is probably more people in NCODA that is not in the publication that has helped. Same in ASCO. Also, we want to give thanks to Dr. Stephen Grubbs, our leader in quality. He's retiring. We're going to miss him, but he has been a key collaborator with Mike organizing these standards for the last five or six years. So, looking forward to these standards in practice. Brittany Harvey: Absolutely. A big thank you to the entire panel and everyone who contributed to this, and NCODA as well. And then finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the complete standards, go to www.asco.org/standards. I also encourage you to check out the companion episode on these standards on the PQI podcast by NCODA, which you can find on Apple Podcasts and Spotify. You can also find many of our standards and interactive resources in the free ASCO Guidelines app, which is available in the Apple App Store or the Google Play Store. If you have enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

S4:E172 The Weekly Update and then Paul Interviews MPath Cofounder and CEO Dr. Dave Miller. MPath is an EMR enabled SaaS platform that identifies individuals who need a preventive care service, provides them personalized education and connects them to needed preventive care. Next week we have a special guest, Senate Banking Committee Chief Counsel Ammon Simon, who will answer questions about proposed legislation to reform the accredited investor definition. Paul and I will also be briefly discussing the regulation of Startup Funds and some of the specifics about the RollingSouth ATDC Fund as a tool for startup investing. (interview recorded 4.24.25)Follow David and Paul: https://x.com/DGRollingSouth https://x.com/PalmettoAngel Connect On LinkedIn: https://www.linkedin.com/in/davidgrisell/ https://www.linkedin.com/in/paulclarkprivateequity/ We invite your feedback and suggestions at www.ventureinthesouth.com or email david@ventureinthesouth.com. Learn more about RollingSouth at rollingsouth.vc or email david@rollingsouth.vc.

With all of the AI implementation into EHR and EMR systems, there is concern about how providers rely on these AI shortcuts more than ever. Without proper safeguards, accountability, and compliance perimeters, relying on AI could be problematic. Terry discusses the red flags to look for and how to proceed with caution in this new […] The post Did you know AI is integrated into EMRs? appeared first on Terry Fletcher Consulting, Inc..

Join us on the latest episode, hosted by Jared S. Taylor!Our Guest: Andrew Hines, Founder & CTO at Canvas Medical.What you'll get out of this episode:Canvas Medical empowers ambulatory practices with a powerful EMR that supports in-person, telehealth, and multi-setting care delivery.Developer tools enable rapid innovation, allowing practices to solve workflow issues and build custom extensions in under a day.Built for practices with a vision, Canvas Medical thrives in settings where teams want to iterate their care models using software and AI.Supports complex, high-touch care specialties like dementia, renal disease, pediatrics, and oncology with AI-powered optimization.Trusted by growing practices, Canvas Medical handles smooth transitions from legacy systems, helping clients future-proof their operations.To learn more about Canvas Medical:Website https://www.linkedin.com/company/canvas-medical/Linkedin https://canvasmedical.com Our sponsors for this episode are:Sage Growth Partners https://www.sage-growth.com/Quantum Health https://www.quantum-health.com/Show and Host's Socials:Slice of HealthcareLinkedIn: https://www.linkedin.com/company/sliceofhealthcare/Jared S TaylorLinkedIn: https://www.linkedin.com/in/jaredstaylor/WHAT IS SLICE OF HEALTHCARE?The go-to site for digital health executive/provider interviews, technology updates, and industry news. Listed to in 65+ countries.

In this follow-up to our last episode on MIPS (Merit-Based Incentive Payment System), Dr. Heather Signorelli takes a deeper dive into what physicians need to know to maximize Medicare reimbursements and avoid penalties. We unpack the four MIPS categories—Quality, Promoting Interoperability, Improvement Activities, and Cost—and how they impact your final score. You'll also hear real-world examples of specialty-specific metrics, tips for leveraging your EMR for MIPS success, and how group vs. individual reporting works. Whether you're new to MIPS or just looking to improve your performance, this episode is packed with actionable insights to help you stay compliant and boost revenue. 

Pediatrician and holistic wellness expert Noemi Adame discusses her article, "Having a female doctor is better for your health, but not for hers." She highlights research indicating patients often experience better outcomes—including lower mortality, readmission, and post-surgical complication rates—when treated by female physicians, potentially linked to factors like longer visits and stronger adherence to guidelines. However, Noemi contrasts this with the significant personal toll on female doctors, who face higher burnout rates, a greater burden of uncompensated tasks like EMR messages (receiving 25 percent more requests), and a concerning lack of the longevity advantage seen in the general female population. She critiques the corporate medical system for failing to adequately support or compensate female physicians for the qualitative differences in their care delivery and the associated emotional labor. Noemi strongly advises female colleagues to protect their own well-being by considering alternatives to corporate employment, such as Direct Primary Care (DPC), independent contracting, or building a personal brand, while also acknowledging the unique challenges women face in setting boundaries within these models. Actionable takeaways emphasize the critical need for female physicians to prioritize self-care, implement sustainable practice systems, and advocate for themselves, whether inside or outside traditional employment structures. Our presenting sponsor is Microsoft Dragon Copilot. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Now you can streamline and customize documentation, surface information right at the point of care, and automate tasks with just a click. Part of Microsoft Cloud for Healthcare, Dragon Copilot offers an extensible AI workspace and a single, integrated platform to help unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise—and it's built on a foundation of trust. It's time to ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended

This episode's Community Champion Sponsor is Ossur. To learn more about their ‘Responsible for Tomorrow' Sustainability Campaign, and how you can get involved: CLICK HEREEpisode Overview: Healthcare's integration challenges have reached a critical juncture where clinicians demand seamless technology that enhances rather than hinders patient care. Our next guest, John Orosco, is revolutionizing this landscape as CEO of Red Rover Health. With over 25 years of healthcare IT experience, including his foundational role at Cerner developing their first API platform, John witnessed firsthand how rigid integration systems stifle innovation. This insight led him to co-found Red Rover Health, creating a normalized SaaS platform that serves as "the App Store for healthcare." By enabling true best-of-breed solutions through standardized APIs, John is breaking down the barriers that have long frustrated healthcare organizations. Join us to discover how Red Rover's pioneering approach is empowering providers to choose the tools they need while maintaining seamless EHR connectivity. Let's go!Episode Highlights:Healthcare's open integration platforms often get shut down when they threaten vendor sales of proprietary solutionsRed Rover Health serves as "the App Store for healthcare," enabling seamless third-party app integration with EHR systemsThe joke "if you've seen one HL7 interface, you've seen one" reflects how every integration requires custom codeHealthcare CIOs often function as "EMR administrators" rather than true technology innovatorsAI/ML represents the next frontier, with Red Rover positioning to enhance data access with AI-powered insightsAbout our Guest: John is a healthcare IT entrepreneur and expert in Electronic Health Record (EHR) integration with over 25 years of experience. He started as a software developer at Cerner Corporation, where he led the first Millennium RESTful integration team. John later founded JASE Health, providing custom EHR integrations for healthcare IT vendors, before co-founding Red Rover Health to develop a normalized SaaS platform for EHR integration. John is dedicated to solving complex EHR challenges and enabling healthcare providers to implement best-of-breed solutions regardless of their EHR system.Links Supporting This Episode: RedRover Health Website: CLICK HEREJohn Orosco LinkedIn page: CLICK HERERed Rover Health LinkedIn: CLICK HEREMike Biselli LinkedIn page: CLICK HEREMike Biselli Twitter page: CLICK HEREVisit our website: CLICK HERESubscribe to newsletter: CLICK HEREGuest nomination form: CLICK HERE